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ABSTRACT

This dissertation presents two applications of discrete-event simulation (DES) to
represent clinical processes: (1) a model to quantify the risk of the maternal obese and
diabetic intrauterine environment influence on progression to adult obesity and diabetes,
and (2) a model to evaluate health and economic outcomes of different smoking cessation
strategies. The first application considers the public health impact of the diabetic and
obese intrauterine environment‘s effect on the prevalence of diabetes and obesity across
subsequent generations. We first develop a preliminary DES model to investigate and
characterize the epidemiology of diabetes during pregnancy and birth outcomes related to
maternal obesity and diabetes. Using data from the San Antonio Heart Study (SAHS), the
1980 Census and the NCHS we are able to verify a simplified initial version of our
model. Our methodology allows us to quantify the impact of maternal disparities between
different racial/ethnic groups on future health disparities at the generational level and to
estimate the extent to which intrauterine exposure to diabetes and obesity could be
driving these health disparities. The populace of interest in this model is women of childbearing age.
The preliminary model is next modified to accommodate data and assumptions
representing the United States population. We use a mixed-methods approach,
incorporating both statistical methods and discrete event simulation, to examine trends in
weight-gain over time among white and black women of child-bearing age in the US
from 1980 to 2008 using United States Census projections and National Health and
Nutrition Examination Survey (NHANES) data. We use BMI as a measure of weight
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adjusted for height. We establish an underlying population representative of the
population prior to the onset of the obesity epidemic. Assessing the rate of change in
body mass index (BMI) of the population prior to the obesity epidemic allows us to make
―unadjusted‖ projections, assuming that subsequent generations carry the same risk as the
initial cohort. Unadjusted projections are compared to actual trends in the US population.
This comparison allows us to quantify the trends in weight-gain over time. This model is
interesting as a first step in understanding the trans-generational impact of obesity during
pregnancy at the population level.
The aim of the second application is to understand the impact of different
pharmacologic interventions for smoking cessation in achieving long-term abstinence
from cigarette smoking is an important health and economic issue. We design and
develop a clinically-based DES model to provide predictive estimates of health and
economic outcomes associated with different smoking cessation interventions.
Interventions assessed included nicotine replacement therapy, oral medications
(bupropion and varenicline), and abstinence without pharmacologic assistance. We
utilized data from multiple sources to simulate patients‘ actions and associated responses
to different interventions along with co-morbidities associated with smoking. Outcomes
of interest included estimates of sustained abstinence from smoking, quality adjusted life
years, cost of treatment, and additional health-related costs due to long-term effects of
smoking (lung cancer, chronic obstructive pulmonary disease, stroke, coronary heart
disease). Understanding the comparative effectiveness and intrinsic value of alternative
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smoking cessation strategies can improve clinical and patient decision-making and
subsequent health and economic outcomes at the population level.
This dissertation contributes to the field of industrial engineering in healthcare.
US population-level data structures are not always available in the desired format and
there is not one method for managing the data. The key element is to be able to link the
mathematical model with the available data. We illustrate various methods (i.e. bootstrap
techniques, mixed-effects regression, application of probability distributions) for
extracting information from different types of data (i.e. longitudinal data, cross-sectional
data, incidence rates) to make population-level predictions. Methods used in costeffectiveness evaluations (i.e. incremental cost-effectiveness ratio, bootstrap confidence
intervals, cost-effectiveness plane) are applied to output measures obtained from the
simulation to compare alternative smoking cessation strategies to deduce additional
information. While the estimates resulting from the two models are topic-specific, many
of the modules created for these studies are generic and can easily be transferred to other
disease models. It is believed that these two models will aid decision makers in
recognizing the impact that preventative-care initiatives will have, and to evaluate
possible alternatives.

iv

DEDICATION

This dissertation is dedicated to my two wonderful sons, Alex and Colin. I hope
this work will motivate and encourage you to reach for your dreams.

v

ACKNOWLEDGMENTS

I would like to thank those who have helped and encouraged me during my
graduate studies.
First, to my advisor Dr. Maria Mayorga, I give a heartfelt thank you for having
faith in me and giving me this opportunity. I have been incredibly fortunate to have an
advisor who is actively involved with her students and who is not only accessible but
willing to help. Thank you for enlightening me through your knowledge and for
providing constructive criticisms. Thank you for always pushing me to be better. Your
insightfulness, advice and leadership are valuable resources that will guide me throughout
my career and from which I will continue to learn.
I would like to extend a special thanks to my committee members Dr. Mary
Elizabeth Kurz, Dr. Byung Rae Cho, and Dr. Kevin Taaffe for their guidance over the
last few years. I am grateful for the insightful comments each of you has provided and for
challenging me along the way. This work is stronger because of your recommendations
and wisdom.
All of the faculty and staff in the Department of Industrial Engineering deserve
recognition for their assistance over the last few years. I am grateful for the friendships of
many current and former graduate students who I have been fortunate enough to meet
during my time at Clemson.
My parents, Melinda and George, have been extremely generous throughout many
long years of education that led me to this point. I extend a very sincere thank you for
always being supportive and willing to go out of your way to do anything you could to

vi

make this process easier. You have instilled in me by example the importance of hard
work, perseverance, and personal sacrifices. Thank you for your unwavering love and
support throughout this process. I also show appreciation to my sister Rima whose
tenacity to reach her own dreams has inspired me.
I am grateful for my grandparents, Alex and Vera, for the many lessons they have
taught me over the course of my life. You have played a significant role in shaping the
person that I am today. Thank you for always being a constant source of unconditional
love and strength.
I thank my husband Clark who has, alongside me, endured six demanding years
of graduate school. You have accommodated long hours of work and a hectic schedule as
a result of my efforts to manage family life and pursue my degree. Thank you for being
proud and supportive of me and thank you for the sacrifices you have made to help me
accomplish my goals.
Last but not least, I express thankfulness to my children Alex and Colin, who
have inspired me in numerous ways. You both are an incredible source of happiness.
Thank you for being the light at the end of the tunnel.

vii

TABLE OF CONTENTS

Page
TITLE PAGE .................................................................................................................... i
ABSTRACT ..................................................................................................................... ii
DEDICATION ................................................................................................................. v
ACKNOWLEDGMENTS .............................................................................................. vi
LIST OF TABLES ........................................................................................................... x
LIST OF FIGURES ....................................................................................................... xii
CHAPTER
1. INTRODUCTION ............................................................................................ 1
1.1
1.2
1.3
1.4

Background ........................................................................................... 1
Research Aims ...................................................................................... 2
Literature Review.................................................................................. 4
Dissertation Organization ................................................................... 15

2. A DISCRETE-EVENT SIMULATION MODEL TO PREDICT
LONG-TERM IMPACTS OF INTRAUTERINE EFFECTS ON
DIABETES AND OBESITY PREVALENCE ............................................... 17
2.1
2.2
2.3
2.4
2.5

Model Introduction ............................................................................. 17
Model Description and Assumptions .................................................. 18
Model Verification .............................................................................. 25
Results ................................................................................................. 27
Conclusions ......................................................................................... 35

3. TRENDS IN WEIGHT-GAIN AMONG WHITE AND BLACK
WOMEN OF CHILDBEARING AGE IN THE UNITED STATES ............. 37
3.1
3.2
3.3
3.4

Introduction ......................................................................................... 37
A Model of the Population Prior to the Onset of the
Obesity Epidemic .......................................................................... 41
Unadjusted Population Weight-Gain Projections ............................... 47
Simulation Parameters and Results ..................................................... 57

viii

Table of Contents (Continued)
Page
3.5

Discussion ........................................................................................... 63

4. A DISCRETE-EVENT SIMULATION MODEL TO ESTIMATE
HEALTH AND ECONOMIC OUTCOMES OF SMOKING
CESSATION TREATMENTS ....................................................................... 68
4.1
4.2
4.3
4.4
4.5

Model Introduction ............................................................................. 68
Model Assumptions and Data ............................................................. 70
Health and economic measures ........................................................... 82
Model Accreditation ........................................................................... 87
Conclusions ......................................................................................... 88

5. ESTIMATING COST-EFFECTIVENESS OF ALTERNATVE
SMOKING CESSATION STRATEGIES ...................................................... 90
5.1
5.2
5.3
5.4

Incremental cost-effectiveness ratio ................................................... 90
Base-case analyses .............................................................................. 93
Uncertainty Analyses ........................................................................ 101
Discussion ......................................................................................... 107

6. CONTRIBUTIONS ...................................................................................... 109
APPENDICES ................................................................................................................ 115
A. Conditional Probability of Diabetes.............................................................. 116
B. DES Distribution Input Parameters and Sensitivity Analysis ............................
Results ..................................................................................................... 118
C. Sample SAS Code ......................................................................................... 122
D. Computations for the Smoking Cessation DES Inputs ................................. 124
REFERENCES ............................................................................................................... 128

ix

LIST OF TABLES

Table

Page

2.1
2.2
2.3
2.4
2.5
2.6

Birth rates (births per 1,000 women in specified group), by age. ......................... 23
Probability of diabetes mellitus, by age and obesity status. ................................. 26
Input parameters for baseline BMI (kg/m2) in the simulation. ............................. 27
Change in BMI (kg/ m2) over 7.5 years. ............................................................... 27
Probability of developing GDM, by age. .............................................................. 27
Verification of performance measures. ................................................................. 28

3.1

Data sources used to obtain numbers representing the actual
population. ...................................................................................................... 50
Average BMI (kg/m2) of white women of childbearing age. ............................... 51
Average BMI (kg/m2) of black women of childbearing age................................. 51
Comparison of the Census and simulation age distributions for
white women. .................................................................................................. 61
Average BMI unadjusted and simulation projections for white
women. ............................................................................................................ 62

3.2
3.3
3.4
3.5

4.1
4.2

4.9
4.10
4.11
4.12

Smoking prevalence among adults in the US. ...................................................... 72
Efficacy rates (defined as treatment-specific, CO2-verified,
continuous abstinence rate over a one-year time period, i.e. during
trial follow-up). ............................................................................................... 74
Lifetime probability of developing COPD, by gender and
smoking status. ................................................................................................ 76
Age-standardized rate of stroke per 100,000 person-years, by gender
and smoking status. ......................................................................................... 77
Risk of lung cancer, by smoking status ................................................................ 77
Age-specific, ten-year rate of CHD, by gender, age, and smoking status. ........... 78
Case fatality rates over the time period of interest. .............................................. 80
Probability of recidivism after 12 months continuous abstinence
(defined as non-treatment-specific, prolonged abstinence
beyond 12 months). ......................................................................................... 82
Health state utility values for smoking-related co-morbidity. .............................. 83
Health state utility values for current and former smokers. .................................. 84
Costs (2010 values, $US) of pharmacological treatment...................................... 86
Cost (2010 values, $US) of treating co-morbidity and event costs. ..................... 87

5.1
5.2
5.3
5.4

Implications of the cost-effectiveness plane. ........................................................ 93
Smoking prevalence among those alive at follow-up. .......................................... 94
Prevalence of smoking-related disease. ................................................................ 95
Prevalence of mortality. ........................................................................................ 96

4.3
4.4
4.5
4.6
4.7
4.8

x

List of Tables (Continued)
Table
5.5
5.6
5.7
5.8
5.9
5.10
5.11
5.12

Page
Smoking cessation strategies compared to no treatment. ..................................... 99
Stepwise comparison of smoking cessation interventions – step one................. 100
Stepwise comparison of smoking cessation interventions – step two. ............... 100
Stepwise comparison of smoking cessation interventions – step three. ............. 100
Incremental costs and effects (QALY) of 1,000 bootstrapped
comparisons of Bupropion vs NRT. ............................................................. 102
Quadrant probabilities of bupropion vs. varenicline........................................... 103
Multi-way sensitivity analysis of recidivism rates.............................................. 106
Sensitivity analysis by subset of the base-case population. ................................ 107

xi

LIST OF FIGURES

Figure
2.1
2.2
2.3
2.4
2.5
2.6

3.1
3.2
3.3
3.4
3.5

Page
Top-level schematic of flow through the simulation. ........................................... 20
Diabetes prevalence (age 18 to 44 years) for increased risk of
diabetes due to intrauterine exposure to maternal obesity. ............................. 32
Diabetes prevalence (age 18 to 29 years) for increased risk of
diabetes due to intrauterine exposure to maternal obesity. ............................. 33
Diabetes prevalence (age 30 to 34 years) for increased risk of
diabetes due to intrauterine exposure to maternal obesity. ............................. 33
Diabetes prevalence (age 35 to 39 years) for increased risk of
diabetes due to intrauterine exposure to maternal obesity. ............................. 34
Diabetes prevalence (age 40 to 44 years) for increased risk of
diabetes due to intrauterine exposure to maternal obesity. ............................. 34
Plot of BMI (kg/m2) vs. Age by birth year cohort for white women,
regression parameters and results shown in table insert. ................................ 46
Plot of BMI (kg/m2) vs. Age by birth year cohort for black women,
regression parameters and results shown in table insert. ................................ 47
Difference in average BMI (NHANES-unadjusted projections) by
year and age cohort of white women. ............................................................. 53
Difference in average BMI (NHANES-unadjusted projections) by
year and age cohort of black women. ............................................................. 54
Unadjusted projections vs. NHANES for white and black women
of childbearing age. ......................................................................................... 56

4.1

High-level schematic of simulation flow. ............................................................. 71

5.1

Incremental cost-effectiveness plane (NE = northeast quadrant;
NW = northwest quadrant; SE = southeast quadrant; SW = southwest
quadrant; QALY = quality adjusted life year). ............................................... 92
Average discounted cost and effect of the five treatment arms
(with 95% CIs). ............................................................................................... 98
Scatter plot of the 1,000 bootstrap pairs presented on the costeffectiveness plane of bupropion vs. varenicline. ......................................... 103
One-way sensitivity analysis of treatment efficacy of bupropion
and varenicline. ............................................................................................. 105
One-way sensitivity of treatment cost of bupropion and varenicline. ................ 105

5.2
5.3
5.4
5.5

xii

CHAPTER ONE
INTRODUCTION

Disease prevention and control remains a crucial health issue and as costs
associated with providing health care services spike, patient choices and care become
more limited. In recent years mathematical modeling of disease dynamics has been used
to answer health care questions. Integrating analytical techniques into public health
research, policy, and practice can help lead clinicians and health policy decision makers
to make recommendations and identify appropriate public health actions to help prevent
disease, improve patient health, and manage rising health care costs. In this dissertation
we provide two examples of predictive models for disease management: (1) a model to
predict the impact of maternal obesity during pregnancy on the prevalence of obesity in
subsequent generations at the population level across different racial and ethnic groups
and to identify health disparities among these groups, and (2) a model to provide
predictive estimates of health and economic outcomes associated with different smoking
cessation interventions.
1.1

Background
Costs of health care have continued to increase for many years. ―Expenditures in

the United States on health care surpassed $2.3 trillion in 2008, more than three times the
$714 billion spent in 1990, and over eight times the $253 billion spent in 1980.‖ [Kaiser]
Health care costs associated with treating chronic diseases in the United States are an
estimated 75 percent of national health expenditures. [CDC1] Approximately one in two
adults in the US (133 million individuals) in 2005 had at least one chronic illness [Wu
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and Green, 2000]. With an increase in the prevalence of chronic illness comes the
increasing need for understanding of disease and persistent management and treatment of
disease.
Mathematical models of disease provide both understanding and prediction of
disease in a population. Modeling of disease dynamics has been used to choose the most
effective interventions for preventing and treating disease, understand population
robustness to disease threats, understand the clinical effectiveness and comparative value
of different treatment strategies, screen an at-risk population for early signs of a disease,
understand infectious disease transmission, understand the impact of individual behavior
and decision making on population-level disease outcomes, predict the future population
with a given disease, guide resource allocation decisions in health care (e.g., distributing
funds, allocating organs for transplantation), and influence insurance coverage decisions
(refer to Section 1.2). Information provided by analytical health care models contributes
to informed decision-making of public policies impacting human life and health. Small
increases in the efficiency of the health care system not only lead to improved patient
outcomes but contribute to tremendous cost savings.
1.2

Research Aims
This dissertation presents two applications of discrete-event simulation (DES) to

estimate long-term epidemiologic and economic consequences of disease processes.
Thereby, this dissertation is compiled of work from two separate projects which are
similar in their methodological approach.
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For application one, we will first create a base simulation model to predict the risk
of exposure to maternal obesity and diabetes during pregnancy on obesity and diabetes
prevalence in future generations and to examine trends over time. The model will be
verified using data for a single cohort. To enable the utilization of cross-sectional
NHANES data (a nationally representative sample) we will apply bootstrap statistical
methods and mixed-effects regression models. We then validate our method for modeling
changes in attributes over time. We begin with an initial cohort and predict prevalence
rates at baseline. Because we will use cross-sectional data to infer incidence rates, we will
compare predicted values within an age group to actual values in that age group at
baseline. That is, we will validate that individuals take on age appropriate characteristics
according to the baseline cross-sectional values. We model the population prior to the
onset of the obesity and diabetes epidemic. Using input data from different racial and
ethnic groups we will quantify health disparities between groups at the population-level
over time.
Regarding application two, we will describe the development and verification of a
simulation to estimate US population-level health and economic outcomes of smoking
cessation interventions. We will describe how we characterize smoking-related disease
based on the available data. Analyses to understand the comparative effectiveness and
intrinsic value of alternative smoking cessation strategies that can improve clinical and
patient decision-making and subsequent health and economic outcomes at the populationlevel will be explained.

3

1.3

Literature Review
This section discusses health care modeling methodologies and applications

regarding cost-effectiveness analysis, statistical procedures (logistic regression analysis
and Bayesian analysis), decision trees, Markov structures (Markov cohort models and
Markov decision processes), and discrete-event simulation (DES) techniques. Motivation
behind the DES modeling approach selected for our models is discussed. Since the
models presented in this dissertation are the first applications of DES to maternal obesity
and smoking cessation treatment/smoking-related disease risks, DES models applied to
other diseases are reviewed.
1.3.1 Cost-effectiveness analysis
Cost-effectiveness analysis combines information on monetary costs and health
benefits (refer to Chapter 5.3) of medical interventions to provide a relative comparison
of two or more treatment strategies. Health policy-makers use this information to make
informed decisions about allocating resources. Different modeling methods can be
applied to perform economic evaluations. Treatment strategies for a broad array of
diseases including cervical cancer [Mandelblatt et al, 2002], colorectal cancer [McMahon
et al., 2001], psoriatic arthritis [Bansback et al., 2006], depression [Pyne et al., 2010],
morbid obesity [Campbell et al., 2010], mental illness [Dixon et al., 2002], prostate
cancer [Hövels et al., 2009; Ito et al., 2010], HIV [Simpson et al., 2004], and sleep
apnoea-hypopnea [Sadatsafavi et al., 2009], among many others, have been assessed
using cost-effectiveness analysis. Chapter 4.1 provides a detailed review of modeling the
cost-effectiveness of smoking cessation strategies.
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1.3.2

Statistical procedures
Chhatwal et al. (2009) developed two logistic regression models to facilitate early

breast cancer diagnosis where the probability of cancer is the outcome measure in each
model. These logistic regression models used mammographic features to make breast
cancer risk predictions which suggest that more accurate decisions may be made using
the probability of cancer estimated in the two models. However, the results do not
recommend when the decision should be made to biopsy a particular patient based on
their risk of breast cancer, and do not consider how patient‘s risks and decisions change
when individual patient attributes (e.g. age) are taken into account.
Many authors have been successful at creating prognostic models of disease using
Bayesian structures to quantify the probability of a disease based on epidemiologic,
demographic, and clinical information. Bayesian models of disease risk for breast cancer
[Burnside et al., 2009; Velikova et al., 2009], prostate cancer [Smith et al., 2009], and
end-stage renal disease [Dimitrov et al., 2003] have been proposed. A predictive model of
patients with carcinoid was developed by van Gerven et al. (2008) using Bayesian
inference. Models of survival prediction [Jayasurya et al., 2010] and prediction of local
failure [Oh et al.; 2011] in lung cancer patients have adopted the Bayesian approach.
Bayesian networks of gene interactions have been constructed by Armañanzas et al.
(2008) and Chen et al. (2006).
Medical data is often hard to accumulate and Bayesian networks are efficient
when information is lacking in comparison with other modeling methods. Nonetheless, to
define probabilistic relationships between diseases and symptoms, Bayesian models
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assume a simple representation of attributes where each problem instance revolves
around predefined attributes. This is insufficient for medical applications in which patient
attributes are uncertain, cannot be defined in advance, and change over time.
Interdependencies among related entities cannot be specified in advance. Because of the
complex nature of disease, clinical models often require a large state space. In Bayesian
network modeling the size of the model space is large when few variables are included
and increases exponentially when variables are added.
1.3.3

Markov structures
Previous models of disease most frequently used Markov structures. Sonnenberg

and Beck (1993) provide an overview of Markov modeling to inform medical decisions.
Markov models have been used to conceptualize Alzheimer‘s disease [Macdonald and
Pritchard, 2000], depression [Le Lay et al, 2006], sepsis [Bauerle et al, 2000], human
papillomavirus (HPV) infection and cervical carcinogenesis [Myers et al, 2000; Dasbach
et al, 2006], HIV [Simpson et al, 2009], and Type 2 diabetes [The CDC Diabetes Costeffectiveness Group, 2002].
A review of Markov models for coronary heart disease (CHD) interventions is
discussed in detail in Cooper et al (2006). Decision tree analysis was typically used to
model acute or short-term CHD interventions and Markov models represented chronic or
long-term CHD interventions. While the majority of CHD studies evaluated the costeffectiveness of treatment strategies, models were also developed to predict the
prevalence of heart disease on the future population.
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The Markov approach describes the transition of a homogeneous cohort of
patients through health states over time. That is, portions of the cohort of patients move
through the model from one event to another based on the likelihood of moving between
states. Markov modeling does not represent and evaluate individuals progressing through
the model. Markov models require mutually exclusive branches or rigidly defined health
states which must signify every aspect of the disease and transition at fixed cycles. Since
the individual can only be in one state at a given time, multiple distinct states are required
to represent all combinations of patient characteristics. The following examples are
adapted from Caro (2005). At least four states must be defined to represent the
combination of obese (yes/no) and diabetic (yes/no) using Markov models. In some
instances it is required that a continuous characteristic (e.g. weight-gain) be modeled as
discrete (yes or no versus how much weight gained). A large number of states would be
required to attempt to capture the continuous nature of the weight-gain attribute. Consider
a change in weight of ±40 pounds which would require almost 20 states to reflect
changes in weight in five pound increments. This problem is exacerbated if new states are
generated over time. For example, week one after treatment represents one state, week
two after treatment represents another state, and so forth. Similarly, the state space
increases if the course of a disease is influenced by the individual‘s history (e.g. history
of an event such as a stroke). Markov models may not be suitable in tracking a patient‘s
disease history properly as they are too limited to consider multiple patient-specific
demographic and health characteristics in a single model. Restrictions arise with high
state-space complexity because as the size of the state space increases, the problem
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becomes harder to solve and can lead intractable solutions. Additionally, Markov chains
are not compatible when a decision needs to be made at multiple points in time.
Health care models involving medical treatment decisions have been formulated
as Markov decision processes (MDPs) to help patients/clinicians design individualized
treatment strategies which provide optimal clinical outcomes. Schaefer et al (2004)
provides a good overview of MDP methodology and summarizes the MDP framework in
terms of medical decision making. Schaefer et al (2004) also summarize several MDP
applications to medical treatment decisions including the optimal control of an epidemic
[Lefevre, 1981], a drug infusion plan for dispensing anesthesia [Hu et al., 1996], kidney
transplantation [Ahn and Hornberger, 1996], mild hereditary spherocytosis treatment
[Magni et al., 2000], ischemic heart disease (IHD) interventions [Hauskrecht and Fraser,
2000], breast cancer screening and treatment options [Chhatwal et al, 2010], and liver
transplantation [Alagoz et al, 2002]. Pneumonia-related sepsis (Kreke et al., 2008),
ventricular septum defect [Peek, 1999], HIV therapy [Shechter et al., 2008], type 2
diabetes treatment [Denton et al, 2009], and liver transplantation [Alagoz et al., 2004,
2007a, 2007b; Sandikci et al., 2008] are also among the studies in this area.
MDPs encompass similar limitations of standard Markov models but comprise
additional challenges. Transition probabilities and rewards could vary based on each
decision made therefore for every possible description of patient health and decision
enough observations must exist to accurately estimate the transition probabilities. For
example, the information contained in the state could be a state-action pair for which no
clinical observations were taken. Therefore, MDPs are more data intensive than other
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stochastic modeling techniques and the limitations regarding available data may make the
state space larger and unfavorable.
1.3.4

Discrete-event simulation
In recent years, discrete-event simulation (DES) has emerged as the preferred

method to characterize clinical processes [Caro 2005; Caro et al., 2010; Karnon and
Brown, 1998]. Le Lay et al. (2006) reviewed Markov models of depression to identify
methodological weaknesses. A DES of major depression was developed to illustrate the
benefits of DES in representing disease progression. The performance of a published
Markov model of HIV was compared to a new DES model of HIV in Simpson et al.
(2009). The authors summarize the strengths and weaknesses of the Markov approach
and DES approach in estimating the cost-effectiveness of two antiretroviral HIV
treatments. Caro et al. (2010) discuss issues with the Markov cohort approach applied to
treatment for heart disease. Furthermore, Ramwadhdoebe et al. (2009) explain when DES
is the appropriate modeling technique and how to apply DES to health care modeling
using pediatric ultrasound screening for hip dysplasia as an example. The authors discuss
the DES model building process and explain the use of the model for informing health
care policy makers.
DES modeling provides a comprehensive evaluation of patients progressing
through the model, based upon individual-level demographic and health attributes (e.g.
age, gender, body-mass index). Patients with differing attributes move from one event to
another in sequential order while simultaneously taking into account important risk
factors such as age, gender, disease history and a patient‘s attitude towards treatment,
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together with any disease-related events (e.g. adverse/acute events such as a stroke or
heart attack). Probabilities of transitioning between health states can be functions of the
clinical and demographic measures and can therefore be dependent upon these
background attributes. For example, gender and age could be assigned independently but
the patient‘s body mass index (BMI) could depend on the gender and age attributes.
Individual-based modeling allows different entities to experience different events, and the
system behavior is a summary of each patient‘s unique clinical history, allowing for
examination of health and economic outcomes at both the individual and population
levels. Since DES modeling allows individual attributes to be included in the model,
compound health states do not have to be defined thus improving the model precision [Le
Lay et al., 2006; Cooper et al., 2006; Simpson et al., 2009].
Entities in a DES model can interact and compete with one another [Shechter et
al., 2005]. Timing of interactions can be independent of fixed length Markov cycles or
completely stochastic. Each interaction between individuals can generate a change in the
state of the system. The path that each participant follows is not necessarily known a
priori therefore it can be influenced by random local events or changes in the system
caused by entities moving through the system. The chance for each of the different
pathways can be assigned by stochastic distributions or fixed probabilities. Since DES
draws random samples from distributions to variations around the mean, information
regarding the effect of statistical uncertainty in model input(s) is provided. It is possible
that a patient re-enters or follows the same pathway in the same run. DES is useful in
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modeling recursive or random events and is a good approach if one has a very large state
space to model.
DES models allow for the creation of lifetime scenarios even though data only
exists for shorter durations. DES has better long-term predictive validity compared to
Markov models as DES has the capability to predict more detailed outcomes, thereby
representing the course of a disease more naturally with few limitations. DES allows
evaluation of multifaceted stochastic systems and for consideration of probable changes
in those systems due to different sources of variation. The user can easily perform
probabilistic sensitivity analysis to study variation in the mean simulation output(s) of a
model as one or more input parameters are varied. Thus, practitioners can identify the
most important factors in a large discrete-event simulation. Additionally, the probabilistic
element of DES allows one to plot the relationships between significant model outputs to
gain an understanding of how different model predictions correlate.
DES has been applied to conceptualize HIV/AIDS progression. Bishai et al
(2007) address allocation decisions for antiretroviral treatment (ART) in developing
countries by comparing eight treatment strategies including pharmacologic treatment and
laboratory monitoring. Costs and health outcomes for a cohort of 10,000 HIV-infected
individuals were obtained. The model ran for 10 years (with the possibility of death) and
was updated on a 6 month basis. Multiple data sources were used including the
Multicenter AIDS Study (MACS) and the Women's Interagency HIV Study (WIHS),
published literature, and parameters from clinical studies to characterize the progression
of disease prior to ART initiation and after ART initiation. Quantification of the
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incremental impact and cost-effectiveness of the interventions was presented. A DES
model of HIV by Linas et al (2009) compared outcomes of two policies to determine
AIDS Drug Assistance Programs (ADAPs) standards to minimize morbidity, mortality,
and costs. The progression of HIV-infected patients on and off ART was conceptualized.
Data from the Massachusetts ADAP in 2004 established a baseline cohort and five-year
clinical outcomes and program utilization measures were compared. Rauner et al (2005)
developed a DES describing mother-to-child transmission of HIV in sub-Saharan Africa.
Two HIV/AIDS interventions were evaluated to identify potential benefits: (1) antiretroviral treatment (ART), and/or (2) bottle-feeding strategies. The POST methodology
was implemented. This model is unique in that mothers and babies were linked (by
pointers in the entity structure) to one another (i.e. a mother could trace her own mother
in addition to her offspring). To provide an example of why this is useful, if a mother
advanced to AIDS while breastfeeding her child, the likelihood of the child developing
HIV could be altered. A warm-up period of 12 years was required to establish the
baseline population and model outcomes were evaluated after an additional 12 years. A
cost-effectiveness analysis was performed to compare scenarios. Results were sensitive to
assumptions regarding HIV prevalence and baseline infant mortality rate, both dependent
on local conditions and the efficacy of ART.
DES models of coronary heart disease (CHD) have been developed for several
purposes. Babad et al (2002) model prevention strategies for CHD where the baseline
population consists of healthy individuals (i.e. individuals without CHD). Healthy
individuals are simulated until they experience their first coronary event.
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Demographic/clinical attributes included age, sex, systolic blood pressure, total
cholesterol, and smoking. Adverse CHD events included the onset of stable angina,
unstable angina, myocardial infarction (MI), and sudden cardiac death. Mortality from
other cardiovascular disease, stroke, cancer, and all-cause reasons were modeled. Davies
et al (1993) POST methodology was applied. Input measures were taken from three main
sources: (1) The Health Survey for England (HSE), (2) The Framingham study, and (3)
The British Regional Heart Study. This model is referred to in the literature and will be
further identified as the Prevention model. Cooper et al (2002) model CHD progression,
prevention, and intervention strategies for a baseline population of sick individuals (i.e.
individuals with CHD). Individuals in this model experience who an acute coronary event
(e.g. MI, unstable angina) are followed through treatment until reach stable
symptomatic/asymptomatic states or death. Patient characteristics include age, sex,
history of previous events, and the degree of coronary artery vessel disease. Risks in the
model change following different treatment strategies. The POST modeling approach was
used to construct the model. The model by Cooper et al (2002) is referred to in the
literature and will be further identified as the Treatment model. Davies et al (2003) linked
the models of Babad et al (2002) and Cooper et al (2002) to provide a complete structure
of prevention and treatment within the population. The purpose of the model was to
evaluate current and possible future treatment options for the population of England and
Wales. Cooper et al (2008) extended the Treatment model [Cooper et al, 2002] to
perform a cost-effectiveness analysis when drugs are given to patients with CHD to help
prevent adverse coronary events (i.e. myocardial infarction, death).
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Shechter et al (2005) modeled End-Stage Liver Disease (ESLD) using DES to
evaluate the effects of possible changes in liver allocation policies in the US. Data from
the United Network for Organ Sharing (UNOS) and quality-of-life estimates from the
literature populated the model. Longitudinal data from patient data records of the
University of Pittsburgh Medical Center was used to assign an individual‘s clinical
attributes. DES was the chosen methodology to allow individual ESLD patients to
compete for donor organs. Markov structures cannot generate queues or represent
individual patients and patient interactions. Disease-specific Cox proportional hazards
models provided estimates of post-transplant survival (survival estimates for the
likelihood of death by the patient and organ rejection/loss). Outcomes obtained from the
simulation were compared with actual UNOS measures to validate the model.
Davies et al (2004) developed two models of diabetic retinopathy (one for Type 1
diabetes and another for Type 2 diabetes) to evaluate the ideal setting, screening
technique, and frequency of screening for early signs of diabetic retinopathy. The model
was constructed using the POST modeling approach (Davies et al, 1993) and populated
with data from the Wisconsin Epidemiologic Study of Diabetic Retinopathy to represent
the untreated progression of disease. Alternative screening and treatment policies of the
United Kingdom were assessed using cost data from the National Health Service (NHS)
in 2001. Outcomes indicated differences between policies only regarding the costeffectiveness for screening.
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A DES of gastric cancer using the POST modeling approach was developed and
used to evaluate the benefits of screening for Helicobacter pylori infection (Davies et al,
2002). The target population consisted of individuals age 40 and older in the year 2000.
Sources of input data to represent the general United Kingdom population were multiple
including published databases and literature. Discounted and undiscounted output
measures were obtained for costs, morbidity, deaths prevented, and years of life saved.
Results favored a screening program for Helicobacter pylori infection. Roderick et al
(2003) used DES modeling to perform a cost-effectiveness analysis in which population
screening for Helicobacter pylori in preventing gastric cancer and peptic ulcer disease
were compared with no screening. The population of England and Wales was represented
and the POST modeling approach was applied. The authors concluded that Helicobacter
pylori screening may be cost-effective over a time period greater than 25 years.
Gestel et al (2010) applied DES to conceptualize the progression of ocular
hypertension in glaucoma patients and evaluated treatment decisions and effects. Health
state utility values and costs associated with disease status were modeled. Health and
economic outcomes were validated and three treatment strategies were compared using
cost-effectiveness analyses.
1.4

Dissertation Organization
The remaining chapters of this dissertation are organized as follows. Material for

the first application is presented in Chapters 2 and 3. In Chapter 2 we focus on the
development and verification of the obesity and diabetes simulation model. Chapter 3
presents our approach for handling cross-sectional US population-level data structures
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and modifies this simulation to accommodate this data. The material for topic two is
presented in Chapters 4 and 5. The development and verification of the DES model to
compare therapeutic options for smoking cessation is described in Chapter 4. In Chapter
5 the base case results of the smoking cessation simulation are discussed and sensitivity
analysis results are presented. Each chapter provides background information and
associated literature relevant to the chapter, in addition to discussing conclusions and
future research opportunities. The dissertation is concluded with Chapter 6 in which we
summarize the contributions of our research.
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CHAPTER TWO
A DISCRETE-EVENT SIMULATION MODEL TO PREDICT LONG-TERM
IMPACTS OF INTRAUTERINE EFFECTS ON DIABETES AND OBESITY
PREVALENCE

This chapter introduces a discrete-event simulation (DES) model to investigate
the impact of the maternal diabetic and obese intrauterine environment influence on the
diabetes and obesity prevalence in subsequent generations. First, we discuss the
methodology and present a description of the model. We next present and discuss the
verification of the model and provide an example of the type of results that can be
obtained from our model.
2.1

Model Introduction
The goal of this research is to provide quantification of the impact of maternal

disparities between different racial/ethnic groups at the population level on health
disparities affecting the populace in the future, where the populace of interest is women
of child-bearing age. To this end we develop a DES model to predict the affects of
exposure to maternal obesity and diabetes during fetal life on the prevalence of diabetes
in subsequent generations to examine trends over long periods of time. The central
hypothesis is that a mother‘s health influences the health of her offspring which in effect
characterizes the health of the population, thereby influencing the health of future
generations. Understanding the impact of fetal exposure to maternal diabetes and obesity
on future generations will allow estimates to be made regarding the degree to which these
exposures could be influencing health disparities.
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The prevalence of obesity and diabetes continues to increase by epidemic
proportions. A study conducted by the Centers for Disease Control and Prevention (CDC)
between 1991 and 2001 observed an increase in the incidence of diabetes in the American
population by 61% and an increase in the incidence of obesity by 74% [CDC2]. An
analysis performed by the CDC from 2006 to 2008 revealed that the prevalence of
obesity in African Americans was 51% higher when compared with Caucasians and the
prevalence of obesity in Hispanics was 21% higher [CDC3].
As the incidence and prevalence of diabetes continues to escalate, women of
reproductive age have an increased chance of becoming diabetic while pregnant. Diabetes
is unique to women because the disease not only affects the mother‘s health but also
impacts the health of the unborn child [Cowie et al., 2006]. Intrauterine exposure to
maternal diabetes may contribute to the worldwide diabetes epidemic. Obesity during
pregnancy predisposes a woman to develop diabetes. Offspring exposed to maternal
diabetes during gestation may be at higher risk of obesity and diabetes than offspring not
exposed to the intrauterine diabetic environment, which means this exposure may be
driving the obesity and diabetes epidemics. Therefore, understanding the
transgenerational epidemiology of diabetes due to intrauterine programming is important.
2.2

Model Description and Assumptions
This section describes the discrete-event simulation (DES) model to investigate

the impact of intrauterine exposure to diabetes and obesity on the prevalence of diabetes
and obesity in future generations. The underlying assumptions of the simulation are
presented.
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2.2.1 Structure of the simulation
The simulation model was developed using Arena 13.5 (a product of Rockwell
Automation Technologies, Inc.) DES software, which allows for fast execution and
incorporates special purpose features to enhance the modeling of dynamic processes.
Four modules are included in the simulation: (1) creation of individuals, (2) disease
progression, (3) population progression, and (4) statistics. Figure 2.1 provides a
simplified depiction of how individuals flow through the model. The simulation starts
with an underlying population and allows for the creation of new individuals each
successive year. Demographic characteristics are initialized upon entry to the simulation.
Once the individual has reached childbearing age, health measures [i.e. body mass index
(BMI), diabetes status] are updated on an annual basis. Individuals meeting specified
conditions are eligible to reproduce. The offspring appear in the simulation model upon
reaching childbearing age to feed the birth rates and represent the change in population
demographics over time. Once pre-determined standards have been realized, the
individual is removed from the simulation. Output measures are calculated as the
simulation progresses. Various run conditions and input parameters may be modified
such as the number of replications, the run length, characteristics of individuals, and the
number of times an individual can produce offspring. A detailed description of each
module follows.
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Figure 2.1: Top-level schematic of flow through the simulation.

2.2.2 Creation of individuals
The creation module initializes the underlying population and these individuals
can take on attributes according to the characteristics of the population demographics. A
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discrete number of individuals enter the simulation according to one arrival which
represents a single cohort sampled from a chosen population. Upon entry into the
simulation model, demographic characteristics (i.e. age) and pregnancy attributes (i.e.
pregnancy status, number of pregnancies) are initialized. The age structure of the
underlying population was constructed using 1980 US Census data. Since we only
evaluate women of childbearing age, the age range of individuals in the simulation was
restricted. All individuals entering the simulation at baseline are females who are not
pregnant and who are considered to have no previous pregnancies. Baseline BMI is
determined in the disease progression module.
Each individual is also assigned a subset of attributes taking on the characteristics
of the mother. These attributes include clinical information routinely collected at delivery
including maternal age, BMI, diabetic status, and obesity status. The maternal attributes
for the underlying cohort represent the characteristics of a healthy individual. A healthy
individual is characterized as neither diabetic nor obese. In other words, individuals in the
starting population are assumed to not have been exposed to diabetes or obesity in utero.
Transition probabilities are dependent upon these background attributes. For
example, age is assigned independently but the patient‘s BMI (used to determine obesity
status) depends on age and ethnicity. Probabilities of developing diabetes are dependent
on the mother‘s diabetic status, and the individual‘s obesity status and age.
2.2.3 Disease progression
Each year in the system, individuals travel through the disease progression
module which consists of two sub-modules: diabetes disease and body mass index (BMI).
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The diabetes disease sub-module updates a patient‘s diabetic status (diabetic/not
diabetic). The diabetes disease sub-module can consider different types of diabetes (type
I and type II diabetes mellitus) according to the available dataset. Once a patient becomes
diabetic, we assume that the patient remains diabetic until leaving the system. Gestational
diabetes mellitus (GDM) is taken into consideration in the population progression module
as a diagnosis of GDM occurs during pregnancy and does not mean that an individual
had diabetes before conception, or that the individual will have diabetes after giving
birth.
The BMI sub-module assigns starting BMI values in addition to assigning cyclic
changes in BMI. BMI values are updated annually by age group according to a specified
distribution. The model can consider BMI with respect to specific population estimates
for the patient‘s race/ethnic background and gender. A patient‘s BMI can either increase
or decrease each year in the system. BMI values and annual changes in BMI may be
restricted based on what is clinically feasible. BMI levels determine obesity status where
a BMI of 30 kg/m2 or greater classifies an individual as obese.
Fetal exposure to maternal diabetes was considered present if the mother was
diagnosed as diabetic before delivery and absent if the mother was not diagnosed as
diabetic. Transitions from healthy to diabetic are dependent on maternal attributes for
exposed/not exposed to diabetes in utero, as well as the individual‘s obesity status and
age. Offspring are not at risk to become sick (diabetic or obese) until they reach
childbearing age. Upon reaching childbearing age, the offspring are assigned a starting
BMI value based on the same data used to initialize BMI for the underlying cohort.
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2.2.4 Population progression
The population progression module allows individuals to reproduce. Pregnancies
were determined based upon probabilities drawn from NCHS natality files [CDC5]. The
number of pregnancies per individual was restricted to a maximum of eight pregnancies.
Two conditions define the eligibility to become pregnant. An individual must be of
childbearing age and the maximum number of allowable pregnancies must not be
attained. An individual who is not of childbearing age or who has exceeded her
maximum number of pregnancies continues to cycle through the simulation with a chance
of getting sick, but with no possibility of getting pregnant. Pregnancy status is adjusted
with respect to demographic and clinical attributes. The likelihood of getting pregnant is
evaluated with respect to age; however, pregnancy status can be determined according to
the individual‘s race/ethnic group. Pregnant women acquire GDM based on age specific
probabilities and are only considered diabetic for the duration of the pregnancy.
Table 2.1: Birth rates (births per 1,000 women in specified group), by age.
Age cohort
Birth rate
18 - 19
73.2
20 - 24
111.1
25 - 29
113.8
30 - 34
61.2
35 - 39
18.8
40 - 44
3.5

We assume that a pregnancy results in one live birth and the offspring is created
(enters the simulation) the next iteration or simulated year through the system. The health
of an infant is dependent on the mother‘s health. The offspring‘s clinical and
demographic attributes are initialized and the offspring takes on the mother‘s
race/ethnicity. A subset of attributes reflecting the mother‘s attributes is assigned when
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the offspring enters the simulation. That is, the offspring carries intrauterine environment
information into the future. Once the offspring is created the mother progresses through
the model as usual and could become pregnant again in the future. We assume that fortyeight percent of offspring are female (based on US Census figures), and the male progeny
are disposed from the system. Female offspring progress through the model and can
procreate.
An accounting sub-module is embedded within the population progression
module to update the age attribute. Since we are only interested in the prevalence of
obesity and diabetes in women of childbearing age, the simulation updates the age of
individuals within the childbearing age limits. When an individual reaches the upper limit
of childbearing age, the individual is removed from the simulation. Upon leaving the
simulation, attributes of the individual are output to a file and the individual‘s maternal
family history can be viewed.
2.2.5 Statistics
The statistics module updates model outcomes. At any point in time, a cross
sectional analysis can be made of individuals currently in the cohort to provide a
prevalence-based measure of the effect of exposure to a disease. The model can
accumulate population statistics including prevalence rates for obesity, type I and/or type
II diabetes mellitus, and GDM. These prevalence rates can be viewed annually and
cumulatively according to different patient attributes (e.g. age group). Additionally, the
distribution for BMI of individuals in the system can be observed.
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2.3

Model Verification
Several measures were taken to verify the model. To ensure conceptual

verification of the model during the developmental stages, we collaborated with the
Division of Biostatistics and Epidemiology in the Department of Medicine at the Medical
University of South Carolina (MUSC). The model was verified by comparing simulated
measures with data from the 1980 United States Census, the National Center for Health
Statistics (NCHS), and results from the San Antonio Heart Study (SAHS) [Mitchell et al.,
1991, Stern et al., 1984]. Because we desire an initial population that is representative of
the population before the inception of the diabetes and obesity epidemic, numbers were
obtained from the results of the San Antonio Heart Study (SAHS) to provide starting
inputs for BMI values and type I diabetes mellitus status. Estimates of the prevalence of
maternal diabetes during pregnancy were abstracted from population-based literature
[Hunt and Schuller, 2007]. Estimates for the initial cohort represented women ages 18 to
44 years.
The SAHS was an 8-year longitudinal study of diabetes and cardiovascular
disease. The SAHS cohort consists of 5158 men and non-pregnant women between the
ages of 25 and 64 years. Households from three types of San Antonio neighborhoods
were randomly sampled including low-income, inner city which is made up of
approximately 100 percent Mexican Americans, middle-income, and high-income
districts [Mitchell et al., 1991, Stern et al., 1984]. Data from the SAHS baseline and
follow-up for females ages 25 to 44 was used as inputs to the model. Since we did not
have data available for females between the ages of 18 to 24 years, this information was

25

deduced using data from participants ages 25 to 29 years. The sample size of females
between the ages of 18 and 44 years was assumed to be 358. Data from the SAHS
provided inputs for two important components of the simulation, the diabetes disease
sub-module and the obesity disease sub-module.
SAHS data provided the diabetes incidence rates for the diabetes disease submodule. Prevalence of diabetes in the SAHS cohort at baseline over all ages was 1.98
percent. At baseline, obese individuals are assumed to be 6.6 times more likely to
develop diabetes than individuals who were not obese. We derive that at baseline 7.38
percent of obese individuals develop diabetes and 1.09 percent of non-obese individuals
develop diabetes. Annual probabilities of developing diabetes consider obese individuals
to be 10.7 times more likely to develop diabetes than individuals who are not obese.
Using incidence of diabetes over the 7.5 year SAHS period, we derive the annual
likelihood of diabetes based on obesity status using the cumulative geometric distribution
(refer to Appendix A for computations).
Table 2.2: Probability of diabetes mellitus, by age and obesity status.
Age cohort
Not obese
Obese
< 30
0.0009
0.0094
30 – 34
0.0018
0.0211
35 – 39
0.0028
0.0329
40 – 44
0.0026
0.0314
*BMI of 30 kg/ m2 or more is considered obese

SAHS statistics also provided data for the obesity sub-module. Because of the
small sample size, all distributions for BMI were treated as a truncated normal
distribution. A lower and upper bound of (µ-1.5σ) and (µ+5σ) respectively was
established for baseline BMI. Lower and upper bounds for the change in BMI were -σ
and +2σ, respectively. Numbers from the SAHS demonstrate that 13.7% of women ages
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25 to 44 are obese at baseline. These numbers were used to initialize starting BMI values
for the underlying population in the simulation. Yearly change in BMI was based on
statistics for the change of BMI in the SAHS at baseline and at follow-up 7.5 years later.
Table 2.3: Input parameters for baseline BMI (kg/m2) in the simulation.
Age cohort
Mean
St Dev
< 30
23.4683
5.0056
30 – 34
23.6806
4.4092
35 – 39
25.1876
6.6825
40 – 44
25.2332
5.7084
Table 2.4: Change in BMI (kg/ m2) over 7.5 years.
Age cohort
Mean
St Dev
< 30
2.5956
2.8653
30 – 34
2.4881
3.3886
35 – 39
2.4119
2.6218
40 – 44
1.5767
2.1411
Table 2.5: Probability of developing GDM, by age.
Annual probability
Age cohort
of GDM
< 30
0.01
30 – 34
0.03
35 – 39
0.05
40 – 44
0.08

2.4

Results
In this section we substantiate model performance computationally. We show by

comparison of system measures and predicted measures that results obtained from the
model closely represent those obtained from the system. Subsequently, we test different
assumptions regarding the effects of the obese intrauterine environment on the prevalence
of diabetes in the population over the long-term.
2.4.1 Verification results
A cohort of 10,000 individuals was simulated over an eight year horizon. The
childbearing age range was 18 years to 44 years and the age structure was taken from the
1980 US Census. We measured average BMI, prevalence of obesity, and prevalence of
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diabetes to verify accurate representation of disease progression. These output variables
appeared to produce sufficiently small 95% confidence interval (CI) half-widths (HW)
after 15 replications. The model was implemented using Rockwell‘s Arena Software
version 13.5.
First, average BMI and obesity prevalence from the simulation were compared to
SAHS data. Average BMI measured in the simulation at baseline and follow-up was 24.8
kg/m2 and 26.9 kg/m2 (95% CI HW of 0.03 and 0.03, respectively) and data from the
SAHS gave a mean BMI of 24.5 kg/m2 and 26.7 kg/m2 at baseline and follow-up,
respectively. Our model predicts obesity prevalence of 13.8% (95% CI HW of 0.23) at
baseline compared to 13.7% obese at baseline in the SAHS. Prevalence of obesity in the
simulation at follow-up measured 24.7% (95% CI HW of 0.27) and 24.3% of the SAHS
population was obese at follow-up. Next we verified prevalence of diabetes in the
simulation. Projected diabetes prevalence at baseline was 1.95% (95% CI HW of 0.06)
compared to 1.98% in the SAHS at baseline. The simulation measured diabetes
prevalence at 5.86% (95% CI HW of 0.13) and 5.79% of the SAHS population was
diabetic at follow-up.

Measure

Table 2.6: Verification of performance measures.
Baseline
Follow-up
Performance Measure
Simulation SAHS
Simulation SAHS
Average BMI (kg/m2)
24.8 (0.03) 24.5
26.9 (0.03) 26.7
Obesity prevalence (%) 13.8 (0.22) 13.7
24.2 (0.24) 24.3
Diabetes prevalence (%) 1.98 (0.08) 1.98
5.86 (0.13) 5.79
Note: Values in parentheses are 95% CI half-widths

Since the CI half-widths of the simulated performance measures capture the
SAHS numbers, we are 95% confident that the simulation projections and SAHS
measures are statistically the same. Projected measures closely correspond to data from

28

the SAHS therefore we believe that our model accurately predicts the outcome of one
cohort. The performance of the model is assumed to be both a verified implementation of
the system in addition to a valid representation of the system. We believe that our model
can realistically forecast other measurements of interest.
2.4.2 Prevalence of diabetes in future generations
Using SAHS data as simulation inputs we tested different assumptions regarding
the effects of the intrauterine environment on the prevalence of diabetes over the longterm. A cohort of 10,000 individuals progressed through the simulation for 100 years.
Output variables were assessed in 5-year intervals. The rate of change in BMI in the
SAHS population was assumed to remain the same over time.
First, projections of diabetes prevalence were reported without maternal affects
(base case). That is, we assume that future generations carry the same risk of disease as
the underlying population. Next, we projected prevalence of diabetes accounting for
maternal affects. Maternal affects is characterized as an increased risk of disease because
of exposure to maternal disease in-utero. We assume an increased risk of diabetes to the
child if exposed in-utero to maternal obesity to demonstrate the type of estimates that can
be obtained from our model. Projections can also be made assuming an increased risk of
diabetes due to intrauterine exposure to maternal diabetes or both maternal obesity and
diabetes. We focus on the influence of exposure to maternal obesity during fetal life
because obesity is considered a dominant trait driving America‘s diabetes epidemic
[CDC4].
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We considered different levels for risk of diabetes in individuals exposed to
maternal disease. Risk factors for diabetes if exposed to maternal obesity during fetal life
were 1.5-, 2.0-, 2.5-, and 3.0-fold. For example, a relative risk of 1.5 means that an
individual who was exposed to an obese intrauterine environment has a 50 percent higher
risk of diabetes than someone not exposed.
Regarding base case projections, after 13 years in the simulation individuals less
than 30 years of age who entered the simulation have matured, and after 18 simulated
years individuals who entered the simulation at age 34 or younger have aged. After 23
simulated years all individuals from the underlying population have aged such that
remaining individuals from the initial cohort are between ages 40 and 44 years. Offspring
of the underlying population have entered the model and are less than 30 years of age.
After 30 simulated years none of the base population remains in the simulation, and the
offspring from this base population are still less than age 30. After 35 simulated years the
offspring have matured but do not exceed 34 years of age. After 40 simulated years the
offspring and their offspring have matured but do not exceed 39 years of age. After 45
simulated years the offspring of the initial population and their offspring exist across all
age groups and a steady flow of patients continues through the model.
Prevalence of obesity in the base model without maternal affects does not
incorporate any additional risk to the offspring if the mother was diabetic while pregnant.
As the underlying population ages, we can see a steady increase in the prevalence of
diabetes. Diabetes prevalence steadily increases during the 18 year time period before
any offspring enter the model. The prevalence of diabetes begins to decline at year 18 and
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drops to 3.49 percent after 30 years as the young offspring enter the simulation. As the
children begin to age the prevalence of diabetes climbs to a peak of 11.3 percent after 45
years. The prevalence of diabetes declines to 8.4 percent after 55 years and then slightly
increases again to 9.3 percent after 65 years. Diabetes prevalence begins to stabilize after
65 years reaching a minimum of 8.45 percent and a maximum of 9.56 percent between
years 65 and 100. We observe an increase in the prevalence of diabetes over time even
without consideration of maternal affects.
Figure 2.2 illustrates sensitivity and the expected increase in diabetes prevalence
for individuals age 18 to 44 years. Considering an increased risk of 1.5 for offspring
exposed to maternal obesity in-utero, the prevalence of diabetes begins to stabilize after
65 years at 10.06%. Considering a risk factor of 2 for intrauterine exposure to obesity, the
prevalence of diabetes begins to stabilize after 65 years at 10.51%. Considering an
increased risk of 2.5 for offspring exposed to maternal obesity in-utero, the prevalence of
diabetes begins to stabilize after 65 years at 10.85%. Considering a risk factor of 3 for
intrauterine exposure to obesity, the diabetes prevalence begins to stabilize after 65 years
at 12.19%. We observe that intrauterine exposure to maternal obesity leads to an
intergenerational acceleration in the prevalence of diabetes in the pediatric population.
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Figure 2.2: Diabetes prevalence (age 18 to 44 years) for increased risk of diabetes due to intrauterine
exposure to maternal obesity.

In Figures 2.3, 2.4, 2.5, and 2.6 we show trends in the prevalence of diabetes by
age cohort over time. Observing results across different age groups and across the risk
factors tested, we notice a more considerable change from each age group at baseline in
the prevalence of diabetes with respect to the risk factors tested. Among individuals less
than 30 years of age, predictions were not substantially different from the baseline output.
The prevalence of diabetes for individuals ages 30 and 34 actually experienced a decrease
from the prevalence of diabetes at baseline. The prevalence for diabetes of individuals
age 35 to 39 slightly increased when compared to the base model. We observe the largest
increase in diabetes prevalence of individuals age 40 to 44. Observing prevalence of
diabetes by age cohort, we notice a positive correlation between age and diabetes
prevalence.
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Figure 2.3: Diabetes prevalence (age 18 to 29 years) for increased risk of diabetes due to intrauterine
exposure to maternal obesity.
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Figure 2.4: Diabetes prevalence (age 30 to 34 years) for increased risk of diabetes due to intrauterine
exposure to maternal obesity.
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Figure 2.5: Diabetes prevalence (age 35 to 39 years) for increased risk of diabetes due to intrauterine
exposure to maternal obesity.
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Figure 2.6: Diabetes prevalence (age 40 to 44 years) for increased risk of diabetes due to intrauterine
exposure to maternal obesity.
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2.5

Conclusions
In conclusion, we developed a simulation model to predict the impact of exposure

to maternal obesity and diabetes during fetal life on the prevalence of obesity and
diabetes in subsequent generations and to examine trends over long periods of time. We
made projections of diabetes prevalence assuming an increased risk of diabetes in
offspring exposed to maternal obesity in-utero to provide an example of the type of
projections that can be obtained from our model. Projections could also be made
assuming an increased risk of diabetes due to intrauterine exposure to maternal diabetes
or both maternal obesity and diabetes. Studies have assessed the additive effect of fetal
exposure to both obesity and diabetes but the degree to which adverse effects have on the
developing fetus has not been quantified [Hunt and Schuller, 2007].
These three alternatives for taking into account in-utero exposures (increased risk
of diabetes due to intrauterine exposure to obesity, diabetes, and both obesity and
diabetes) are considered mutually exclusive cases. Since we are analyzing sensitivity with
respect to the same risk factors and obesity prevalence is higher than diabetes prevalence
at baseline, we would expect to notice the largest increase in the prevalence of diabetes
with consideration to intrauterine exposure to maternal obesity. The underlying
prevalence of diabetes is smaller at 1.98% diabetic. We would expect to notice less of an
impact due to the influence of fetal exposure to maternal diabetes than exposure to
obesity during gestation. Since we are assessing the same risk factors for each case and
the percentage of the population that is both diabetic and obese is the smallest, we would
expect to observe a nominal impact over the long-term as a result of exposure to both
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diabetes and obesity in-utero. We speculate that the risk factors associated with maternal
exposure to disease in reality are not the same across the three scenarios.
Verification efforts showed that our model accurately predicts the outcome of one
cohort. However, extrapolation from the SAHS data is not ideal for three reasons. First,
the sample size is small, consisting of a maximum and minimum of 575 and 250 samples
respectively across age categories; second, the SAHS population is not representative of
the national population and does not include African Americans; and third, obesity and
diabetes incidence rates in San Antonio were already relatively high in the early eighties
when the SAHS was initiated. Thus we would like to use baseline data which is large,
accurate, and captures the population before the prevalence of obesity and diabetes
increased.
In this chapter we only look at a specific cohort, however this simulation model
can easily be modified to accommodate different data structures and assumptions. Future
simulations representative of the US population will model subsequent generations
among different racial and ethnic groups and will incorporate information on intrauterine
exposure to obesity and diabetes in determining an individual‘s adult obesity and diabetes
status. Chapter 3 aims to extend this simulation to quantify the impact of maternal
disparities between different racial and ethnic groups at the US population-level on health
disparities affecting the populace in the future.
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CHAPTER THREE
TRENDS IN WEIGHT-GAIN AMONG WHITE AND BLACK WOMEN OF
CHILDBEARING AGE IN THE UNITED STATES

3.1

Introduction
The prevalence of overweight and obesity among US adults have increased by

epidemic proportions since 1980. Over the past 30 years the percentage of the US adult
population that is obese has doubled with approximately 34 percent of adults age 20 years
and over being obese (BMI ≥30 kg/m2) and an additional 34 percent of adults age 20
years and over being overweight (30 kg/m2>BMI ≥25 kg/m2) in 2007-2008 [CDC7]. In
contrast, the prevalence of obesity was relatively stable between 1960 and 1980;
however, there is a noted shift in the early 1980s as can be observed by a striking increase
in the prevalence of obesity between the second and third NHANES (i.e., from 19761980 to 1988-1994) [CDC9, Flegal et al., 1998]. Additional increases in the prevalence of
obesity occurred in the 1990s [CDC9, Flegal et al., 2002]. The prevalence of obesity
varies by racial and ethnic group with minority populations having a higher prevalence of
obesity as well as more severe obesity [Flegal et al., 2010, Ogden et al., 2006].
The causes of the obesity epidemic are not completely understood. Early life
exposures are emerging as potentially important risk factors for adult diseases including
obesity and diabetes. The ―fetal origin of disease‖ hypothesis proposes that gestational
programming may critically influence adult health and disease [Barker, 1995]. As the
prevalence of obesity increases, its impact on childbearing women and their infants also
increases; therefore, the obese in-utero environment may be a cause as well as a result of
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the obesity epidemic. Moreover, trans-generational effects, because of their long term
implications, may also play a role in the perpetuation of the epidemic. Trans-generational
effects include genetic information, shared environment and behaviors passed from one
generation to the next as well as in-utero exposures which may impact gestational
programming. Moreover, if intrauterine exposure to maternal obesity contributes to
initiation or perpetuation of the obesity epidemic, then the prevalence of obesity will not
only increase across all populations, but will disproportionately affect racial/ethnic
groups with a higher initial prevalence of obesity. Hence, understanding the transgenerational impact of obesity may be one key to understanding health disparities.
Because it would take decades to conduct trans-generational studies at the
population level, we instead use a mixed-methods approach, incorporating both statistical
methods and discrete-event simulation (DES), to determine the trans-generational impact
of maternal obesity across multiple racial and ethnic groups at the population level.
Specifically, we examine trends in weight-gain over time among black and white (nonHispanic) women of child-bearing age in the US between 1980 and 2008. This approach
will enable us to model the trans-generational impact of maternal obesity during
pregnancy. While substantial increases in the prevalence of overweight and obesity
among women of reproductive age in the US have occurred over the past several decades,
the mechanisms underlying the obesity epidemic and its contributing factors are not fully
understood. In this chapter, we establish an underlying population representative of the
population prior to the onset of the obesity epidemic and develop a simulation model to
make projections assuming that subsequent generations carry the same risk as the initial
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cohort. We compare the simulation projections to actual trends to estimate the increased
risk in weight-gain over time. Our model uses data obtained from the US Census and the
National Health and Nutrition Examination Survey (NHANES). We use body mass index
(BMI in kg/m2) as a measure of weight adjusted for height.
While the prevalence of overweight and obesity over the past two decades has
been well documented among US adults [Flegal et al., 1998, Flegal et al., 2002, Flegal et
al., 2010, Ogden et al., 2006], few studies specifically focus on women of childbearing
age or on disparities between racial/ethnic groups. In one study, Chu et al. (2009)
estimate the prevalence of prepregnancy obesity in 2004-2005 by analyzing Pregnancy
Risk Assessment and Monotoring System (PRAMS) data. The work we present here goes
beyond estimates of past and current trends; with a simulation model we forecast trends
in weight gain. Several methods exist for conducting projections. Projections can be
made using statistical models applied to population estimates. For example, Kelly et al.
(2008) use prevalence data from 2005 and apply it to population projections to estimate
overweight and obesity prevalence in adults worldwide in 2030. They make two
estimates, one assumes that the prevalence of overweight and obesity remained constant;
the other assumes an increased trend. Our methodology differs from this in that in
addition to estimating actual trends in weight gain from past data and population
estimates, we examine ―unadjusted‖ weight-gain in the population over time assuming
the rate of change in BMI with age of the US population had remained the same as in
1980. We do this by using a simulation model. Other methods used to make projections
include Markov models, such as that used by Honeycutt et al. (2003) to forecast the
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prevalence of diabetes in the US from 2000 to 2050. We choose to use simulation over a
Markov model to model BMI trends for several reasons. First, if we wish to capture BMI
directly (not just prevalence of obesity and overweight), which is dependent on age; the
state space of such a model would be prohibitively large [BMI is a continuous variable
while diabetes was modeled as binary variable in Honeycutt et al. (2003)]. It is important
to be able to capture both BMI and risk by age because risk attributed to diseases of
interest (e.g. diabetes) vary by BMI and the rate of change of BMI is different between
age groups. Secondly, the simulation model allows the rate of change in BMI to vary
over time, and can easily incorporate additional independent variables. This will be
important in later work, where we attempt to explain the difference in the estimated
values between actual trends and predicted trends by assigning risk to the children of
women depending on the BMI level they experienced during pregnancy.
In this chapter we (1) develop a statistical model to assess the change in BMI as a
function of age using data obtained through a cross-sectional study design and (2)
develop and present validation methods for a DES model that examines trends in average
BMI over generations at the population level. The structure of the chapter is organized as
follows. In §3.2, we describe the statistical model and present the results of the data
analysis. In §3.3 we model trends in population weight-gain over time based on the
statistical analysis. We use a simulation model in §3.4 to model weight-gain trends and
provide the validation of the simulation model. The chapter is concluded with a
discussion in §3.5 where future research directions are also presented.
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3.2

A Model of the Population Prior to the Onset of the Obesity Epidemic
In this section we describe a method to enable the utilization of cross-sectional

data to make estimates of change in attributes of individuals over time. We apply our
method to US population-level National Health and Nutrition Examination Survey
(NHANES) BMI data. Our method allows us to characterize weight-gain in white and
black women of childbearing age in the US population prior to 1980 (i.e. before the onset
of the obesity epidemic). The rate of change in weight-gain prior to 1980 was less than
the rate of change in weight-gain between 1980 and 2008. Using the rate of change in
weight-gain before 1980 we model BMI in this population to estimate what the
population would have looked like if the rate of change in weight-gain had not increased.
This model will allow us to quantify the increase in weight-gain by comparing the
simulated population to the actual population over time.
3.2.1 NHANES data
The NHANES program, part of the National Center for Health Statistics (NCHS),
Centers for Disease Control and Prevention involves a sequence of cross-sectional health
examination surveys beginning in 1960 which concentrate on different population groups
and health issues. Each NHANES survey provides a nationally representative sample of
the US non-institutionalized civilian population obtained using a complex, stratified,
multistage probability cluster sampling design [CDC8]. Study periods include three
NHANES surveys (NHANES I, 1971-1974; NHANES II, 1976-1980; and NHANES III,
1988-1994) and continuous NHANES which began in 1999. Beginning in 1999
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NHANES became a continuous surveillance system releasing data in two-year periods
(1999-2000, 2001-2002, 2003-2004, 2005-2006, and 2007-2008).
3.2.2

Method for utilization of cross-sectional data
We apply mixed-effects regression analysis and bootstrap techniques to make

inferences about change in trends in BMI over time using cross-sectional data. Here we
discuss the general steps required to enable the utilization of cross-sectional data to
estimate change in some dependent variable of interest (in our case BMI) over time. Data
is divided into cohorts (in our case defined by birth year) based on two key criterion: (1)
number of available data points of the dependent variable for each possible value of the
independent variable(s) within the cohort, and (2) fit of the regression model. Every
cohort should contain enough data points to constitute a representative sample.
Regression analysis is then performed separately for each cohort. Plots of the best fit
regression line are created for each cohort and the graphs are superimposed. The form of
the overlaid plot should approximate a straight line. If the slopes of the superimposed
lines do not approximate a straight line, cohorts are re-grouped and the process repeats
(regression analysis and evaluation of superimposed graphs).
Linear mixed-effects regression analysis is performed separately for each cohort
to estimate the rate of change in the value of the dependent variable (e.g.. BMI) that
results from changes in the independent variable(s) (e.g. age). A bootstrap resampling
approach is applied to the data for each cohort separately. The size of the bootstrap
sample is determined based on the total number of data points available for each cohort
and the bootstrap sample size is the same across all cohorts. Bootstrapped data points are
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collected over 100 iterations. Bootstrapping provides a sample representative of the
original sample of uniform sample size across all cohorts. Linear mixed-effects
regression models are fit to the bootstrapped sample drawn in each of the 100 replications
thereby providing 100 regression equations. A random effect term accounts for error in
the bootstrap samples which are not consistent across samples. Obtaining multiple
equations allowed us to build a probability distribution around the expected value of the
dependent variable (i.e. BMI) at the intercept, as well as around the rate of change of the
dependent variable according to the independent variable (i.e. age).
3.2.3

Statistical analysis of BMI data
In this section, we apply our method to enable the utilization of cross-sectional

NHANES data to estimate the rate of change in BMI of individuals over time. The
NHANES I and II studies provide large data sets that capture the population before the
prevalence of obesity increased [CDC9]. To obtain the BMI data, NHANES collected
weight and height measurements that were taken through physical examination by trained
health technicians and were conducted in a mobile examination center using standardized
measuring techniques and equipment. Body mass index (BMI) was expressed as weight
in kilograms divided by height in meters squared (kg/m2) [CDC8].
We use linear mixed-effects regression models to estimate age and birth year
cohort effects on BMI values of women ages 15 to 44 years in the US measured during
NHANES I and NHANES II. We assess the relationship between BMI and age to gain
insights into the change in BMI over time when the data is obtained through a crosssectional study design. To avoid cohort effects, data from NHANES I and II surveys were
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concatenated into one data set. The combined NHANES I and II data set was divided into
groups of white women and black women based on birth year. Birth year cohorts were
selected based on the number of available data points from the NHANES I and II surveys
and based on the fit of various regression models evaluated. In our analysis, at least 30
BMI data points for each age represented in a birth year cohort were required to provide a
representative sample. Data for white women was divided into five birth year cohorts:
1955 to 1959, 1950 to 1954, 1940 to 1949, 1935 to 1939, and 1930 to 1934. Data for
black women was divided into two birth year cohorts: 1945 to 1959 and 1925 to 1944.
Regression analysis was performed separately for each birth year cohort to
estimate the rate of change of BMI values stratified by age using SAS version 9.2
(sample SAS code for white women born between 1955 and 1959 is provided in
Appendix C). Sampling weights were included in the regressions to control for unequal
probabilities of selection in the sample design, lack of responsiveness, and areas under
covered so that the numbers represented the US population. Analyses were conducted
using the bootstrap approach to collect repeated random samples from the combined
NHANES I and II dataset where the sampling was done with replacement. A sample of
500 BMI data points was collected from the combined NHANES I and II dataset over
100 iterations. The size of the bootstrap sample was determined based on the number of
NHANES I and II data points available for each birth year cohort, see parameters in
Figures 3.1 and 3.2. Regression analysis was used to fit a model to the bootstrapped BMI
data points sampled in each of the 100 replications thereby providing 100 regression
equations. Obtaining multiple equations allowed us to build a probability distribution
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around the expected mean value of BMI at the intercept, as well as around the rate of
change of BMI values according to age. The resulting distributions are shown in Tables
B.1 and B.2 in the appendix.
3.2.4 Statistical analysis results
The table inserts shown in Figures 3.1 and 3.2 provide the age span for each birth
year cohort, the number of available NHANES I and II data points, the size of the
bootstrap sample, and the regression equations for white and black women, respectively.
We note that the age span for different birth year cohorts overlaps in several cases. The
plots shown in Figures 3.1 and 3.2 display the regression results of BMI versus age
according to birth year cohort for white and black women, respectively. The regression
results for all birth year cohorts are overlaid onto one graph. For white women (Figure
3.1) we see that the estimated BMI for a particular age does not vary significantly by
birth year cohort. The exception occurs over the age span 32 to 37 years. For black
women on the other hand (Figure 3.2), we see that there is a significant difference in the
Beta values associated with the two birth year cohorts. How these differences are handled
is discussed in Section 3.4.4.
These results provide us with a characterization of weight-gain in the population
prior to the onset of the obesity epidemic. The next section describes how the regression
estimates are used to make projections about BMI trends of this population after 1980, if
their risk for weight-gain had not changed over time.
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Figure 3.1: Plot of BMI (kg/m2) vs. Age by birth year cohort for white women, regression parameters and
results shown in table insert.
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Figure 3.2: Plot of BMI (kg/m2) vs. Age by birth year cohort for black women, regression parameters and
results shown in table insert.

3.3

Unadjusted Population Weight-Gain Projections
In this section we recreate the population using the BMI estimates (stratified by

age and race/ethnicity) obtained from the regression analysis in which risk of weight-gain
is the risk in 1980. These ―unadjusted‖ BMI projections reflect trends in this population if
the rate of change in average BMI between 1980 and 2008 remained the same as it was in
the 1980s (i.e. if the rate of change in BMI had not increased after 1980). We compare
differences in BMI from 1980 to 2008 among white and black women of childbearing
age in the US between NHANES BMI estimates (representing the actual population) and
our unadjusted weight-gain projections. We expect the NHANES BMI trends for 1980 to
be statistically the same as the unadjusted projections. We expect NHANES BMI trends
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after 1980 to be higher than the unadjusted projections. The NHANES estimates
(representative of the actual population in a given year) are higher because substantial
increases in the prevalence of overweight and obesity among women of reproductive age
in the US have occurred since 1980 and continue to occur [CDC7]. Comparison of
unadjusted projections and actual trends in weight-gain in the US population allow us to
quantify the increase in incidence rate over time which is not due to change in
demographics over time.
3.3.1 Generation of the unadjusted BMI projections
To make unadjusted projections of this population over time we apply the
regression estimates of BMI to the US Census age distributions according to
race/ethnicity using Arena 13.5 software (a product of Rockwell Automation
Technologies, Inc.). First, the age distribution is assigned using population characteristics
for white and black women ages 15 to 44 years obtained from the US Census [1980,
1990, 2000, and 2008 (Census 2008 values are projected based on Census 2000
numbers)]. Next, age-specific BMI is assigned (independent of birth year cohort)
according to the normal distribution. Age-specific estimates of BMI from the regression
analysis provide the mean value of the distribution. The standard deviation is that of the
actual concatenated NHANES I and II data set. Table B.1 in the appendix provides a
detailed list of the BMI values (mean and standard deviation) by age and race. Arena was
run in eight separate scenarios (for white women and black women in 1980, 1990, 2000,
and 2008) and average BMI was computed for the population age range (15-44) and by
age groups (15-19, 20-24, 25-29, 30-34, 35-39, and 40-44).
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In Figure 3.1 we observe overlaps in the different age cohort regression lines for
white women. When more than one point existed we used the average of the points to
assign mean BMI. For example, in Figure 3.1 two data points exist for white women age
17 years, a point estimated from the regression equation for birth year cohort 1955 to
1959 and a point estimated from the regression equation for birth year cohort 1950 to
1954. BMI for women age 17 years are taken as the average of estimates for birth year
cohorts 1955 to 1959 and 1950 to 1954 from the regression analysis.
3.3.2 Comparison of average BMI
Comparison of unadjusted projections and actual trends in weight-gain among
white and black women of childbearing age in the US population allow us to quantify the
increase in BMI over time not due to age and race/ethnicity. We compare our unadjusted
BMI projections to NHANES BMI data representative of the actual population in 1980,
1990, 2000, and 2008. NHANES estimates are not based on birth year; that is, NHANES
estimates include all individuals between 15 and 44 years of age in the NHANES
datasets. The NHANES dataset(s) most closely corresponding to the projected year was
used as the comparison group. In some instances, more than two years of data were
needed to have adequate sample sizes for analysis therefore NHANES datasets were
combined to provide additional data points. Table 3.1 provides a summary of the specific
NHANES datasets used to obtain BMI values representing the actual population in 1980,
1990, 2000 and 2008.
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Table 3.1: Data sources used to obtain numbers representing the actual population.
Census Year
Comparison BMI
1980
NHANES I and II
1990
NHANES III
2000
NHANES 1999-2002
2008
NHANES 2005-2008

Tables 3.2 and 3.3 show the average unadjusted BMI projections and average
BMI estimates obtained from the NHANES population by age cohort and year.
Parentheses define 95 percent confidence interval half-widths. The projections for 1980
provide a verification of our statistical model. The 95 percent confidence intervals for the
projected numbers and the actual NHANES numbers overlap (shown in Figure 3.6),
therefore we conclude that our projections and actual NHANES numbers are statistically
the same. In other words, the projected population in 1980 (developed from our
regression model) adequately represents the 1980 population of the NHANES data;
furthermore, each age cohort is adequately represented in terms of average BMI.
Furthermore, we can see that beyond 1980, the projected BMI values are less than the
NHANES values; this is true for all age cohorts and for both black and white women.
Furthermore, for the overall population (women ages 15-44) the difference in average
BMI is increasing with time for both black and white women.
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Table 3.2: Average BMI (kg/m2) of white women of childbearing age.
1980
1990
Age
Unadjusted
Unadjusted
Cohorts
NHANES I & II
NHANES III
Projections
Projections
15 - 19
21.94 (0.08)
21.88 (0.22)
21.94 (0.08)
22.69 (0.56)
20 - 24
22.67 (0.07)
22.74 (0.22)
22.70 (0.06)
23.59 (0.71)
25 - 29
23.40 (0.07)
23.33 (0.25)
23.46 (0.07)
24.28 (0.63)
30 - 34
24.23 (0.08)
24.29 (0.29)
24.15 (0.11)
25.46 (0.72)
35 - 39
24.61 (0.10)
24.68 (0.31)
24.64 (0.09)
26.59 (0.81)
40 - 44
25.17 (0.11)
25.13 (0.33)
25.20 (0.12)
26.29 (0.77)
15 - 44
23.48 (0.03)
23.62 (0.11)
23.75 (0.03)
24.82 (0.28)
2000
2008
Age
Unadjusted
NHANES 1999Unadjusted
NHANES 2005Cohorts
Projections
2002
Projections
2008
15 - 19
21.89 (0.08)
23.55 (0.56)
21.90 (0.09)
23.64 (0.60)
20 - 24
22.74 (0.07)
26.06 (1.09)
22.73 (0.05)
26.22 (1.23)
25 - 29
23.47 (0.08)
26.69 (1.03)
23.43 (0.08)
27.30 (1.23)
30 - 34
24.14 (0.10)
26.73 (1.07)
24.14 (0.13)
27.95 (1.06)
35 - 39
24.63 (0.08)
27.40 (1.18)
24.65 (0.08)
27.92 (1.10)
40 - 44
25.21 (0.12)
27.71 (1.11)
25.20 (0.12)
28.90 (1.03)
15 - 44
23.80 (0.04)
25.91 (0.40)
23.69 (0.04)
26.68 (0.42)
Note: Values in parentheses are 95% CI half-widths.

Table 3.3: Average BMI (kg/m2) of black women of childbearing age.
1980
1990
Age
Unadjusted
Unadjusted
Cohorts
NHANES I & II
NHANES III
Projections
Projections
15 - 19
22.96 (0.11)
22.81 (0.58)
23.01 (0.10)
24.71 (0.67)
20 - 24
24.36 (0.09)
24.20 (0.59)
24.38 (0.08)
26.19 (0.68)
25 - 29
25.87 (0.09)
25.70 (0.71)
25.84 (0.08)
27.24 (0.78)
30 - 34
27.03 (0.13)
27.13 (0.90)
27.10 (0.13)
29.05 (0.89)
35 - 39
27.78 (0.16)
28.35 (0.87)
27.77 (0.12)
29.44 (0.81)
40 - 44
28.69 (0.12)
28.37 (0.82)
28.65 (0.16)
30.61 (0.91)
15 - 44
25.59 (0.04)
25.80 (0.31)
26.02 (0.05)
27.78 (0.33)
2000
2008
Age
Unadjusted
NHANES 1999Unadjusted
NHANES 2005Cohorts
Projections
2002
Projections
2008
15 - 19
23.00 (0.09)
25.67 (0.81)
22.98 (0.09)
26.69 (0.86)
20 - 24
24.36 (0.08)
29.05 (1.90)
24.38 (0.07)
29.96 (2.03)
25 - 29
25.88 (0.09)
30.11 (2.02)
25.84 (0.08)
30.66 (1.85)
30 - 34
27.06 (0.14)
31.29 (1.92)
27.09 (0.15)
31.42 (1.56)
35 - 39
27.81 (0.11)
30.10 (1.50)
27.78 (0.12)
32.08 (1.85)
40 - 44
28.65 (0.15)
32.73 (2.00)
28.68 (0.15)
30.75 (1.61)
15 - 44
26.15 (0.05)
28.44 (0.62)
26.01 (0.05)
29.26 (0.61)
Note: Values in parentheses are 95% CI half-widths.
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3.3.1 Comparison of average BMI across age groups
We are interested in the difference between the average BMI of women based on
NHANES (which represents the actual population and trends) and the unadjusted BMI
estimates. Figures 3.4 and 3.5 provide these results by age cohort, for white and black
women respectively. These figures show the differences in average BMI of the NHANES
population and the projected population by age cohort in 1990, 2000, and 2008. For
example, consider the difference in average BMI of white women 20 to 24 years of age in
1990 (0.88 kg/m2). Average BMI computed from the NHANES III dataset represents the
actual population 20 to 24 years of age in 1990 (23.59 kg/m2). Projected average BMI of
individuals age 20 to 24 years in 1990 is 22.70 kg/m2) was obtained by applying our
regression estimates to the Census 1990 age distribution. The difference between the
actual NHANES value and the predicted value (i.e., average BMI of individuals age 20 to
24 computed from the NHANES I and II dataset minus unadjusted average BMI
projections) for individuals age 20 to 24 years in 1990 is 0.88 kg/m2.
Refer to Figure 3.4 for a discussion regarding the difference in average BMI for
white women. The difference in average BMI in 1990 is fairly low (i.e., less than 1
kg/m2) in half of the six groups. In 1990, the difference in average BMI for age cohorts
15 to 19, 20 to 24, and 25 to 29 was comparable ranging from 0.75 kg/m2 to 0.88 kg/m2.
The age group with the largest discrepancy between the simulated and NHANES BMI
values in 1990 were women in age cohort 35 to 39 (1.95 kg/m2). In 2000, the difference
in average BMI across all age cohorts escalated. The difference in average BMI of age
cohort 15 to 19 was the smallest across all age cohorts (1.66 kg/m2). Age cohorts 20 to 24
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and 25 to 29 hold the largest difference in average BMI in 2000 (3.32 kg/m2 and 3.22
kg/m2, respectively). In 2008, we observe a difference in average BMI greater than 3
kg/m2 across all age cohorts except age cohort 15 to 19 (1.73 kg/m2). Difference in
average BMI of age cohorts 15 to 19 and 20 to 24 began to level off between 2000 and
2008.
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Figure 3.3: Difference in average BMI (NHANES-unadjusted projections) by year and age cohort of white
women.

In contrast to white women, the difference in average BMI of black women across
the various age cohorts in 1990 is high (Figure 3.5), ranging from 1.40 kg/m2 to 1.96
kg/m2 (compared to 0.75 kg/m2 to 1.95 kg/m2 for white women). Individuals age 40 to 44
have the largest difference in average BMI (1.96 kg/m2) in 1990. Between 1990 and 2000
the difference in average BMI spikes, particularly among age cohorts 20 to 24 and 25 to
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29, followed by age cohorts 30 to 34 and 40 to 44. In 2000, the difference in average
BMI rises to more than 5 kg/m2 in one age cohort (20 to 24). The difference in average
BMI begins to level off between 2000 and 2008 among individuals age 30 to 34.
Interestingly, between 2000 and 2008 the difference in BMI for black women age 40 to
44 actually decreases by almost 2 kg/m2. This result differs greatly from white women
age 40 to 44, where the difference in average BMI increased considerably between 2000
and 2008.
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Figure 3.4: Difference in average BMI (NHANES-unadjusted projections) by year and age cohort of black
women.

3.3.2 Comparison in trends over time for black and white women of all ages
Next we examine trends in BMI over all ages. In particular, Figure 3.6 compares
average BMI of women of childbearing age (ages 15 to 44) computed from the NHANES
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data sets to projected average BMI of women of childbearing age at baseline (1980) and
for projections in years 1990, 2000, and 2008. NHANES values represent the actual
population each year while the projections show average BMI of the population if the rate
of change in BMI had remained stable (i.e. no additional risk since 1980). The 95 percent
confidence intervals of average BMI for actual NHANES values and unadjusted
projections are displayed. Average BMI of white and black women computed from the
NHANES data sets and the projected values are displayed in one panel to show racial
disparities in average BMI and the rate of change in BMI among white and black women
of childbearing age.
The first important result is that the 95 percent confidence intervals about the
projected numbers and actual NHANES numbers for white and black women age 15 to
44 years do not overlap in years 1990, 2000, and 2008; therefore the projected numbers
and actual NHANES numbers are statistically different for years 1990, 2000, and 2008.
This is true for both white and black women.
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Figure 3.5: Unadjusted projections vs. NHANES for white and black women of childbearing age.

In 1980 black women of childbearing age had a higher baseline BMI level than
white women of childbearing age, with actual average BMI of black women at 25.80
kg/m2 compared to actual average BMI of white women at 23.62 kg/m2, a difference of
approximately 2 kg/m2 (Figure 3.6). Not only did black women start out with a higher
baseline BMI value, but the rate of change in average BMI increased faster in black
women of childbearing age versus white women. Observing actual average BMI of
individuals age 15 to 44 years (i.e. NHANES), we notice that both white and black
women experience a steady increase in average BMI between 1980 and 2008. However,
the rate of change in average BMI of black women increased more rapidly between 1980
and 1990 compared to the rate of change in average BMI of white women during this
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time period. A change in average BMI of 1.98 kg/m2 in black women compared to 1.2
kg/m2 in white women. Between 1990 and 2000, the rate of change in average BMI of
white women was higher than the rate of change in average BMI of black women. White
women experience a change in average BMI of 1.09 kg/m2 compared to 0.66 kg/m2 in
black women. The rate of change in average BMI of black women between 2000 and
2008 again accelerated faster when compared to white women, with a change in average
of 0.82 kg/m2 in black women and 0.77 kg/m2 in white women. Overall, the actual change
in average BMI between 1980 and 2008 was slightly greater among black women of
childbearing age compared to white women (a change in average BMI of 3.46 kg/m2 for
black women and a change in average BMI of 3.06 kg/m2 for white women).
3.4

Simulation Parameters and Results
In this section we use discrete-event simulation (DES) to examine weight-gain

trends in the US population over time. The simulation model is important because it will
allow us (in future research) to make projections of weight-gain in this population after
2008. The simulation model presented in Chapter 2 is modified to make projections
regarding the rate of change in BMI in the US population if substantial weight-gain had
not occurred in the 1980s. The reader should refer to Section 2.2 for a complete
explanation of the simulation structure and assumptions. Our method for validating
average BMI simulation projections from 1980 to 2008 is described.
3.4.1 Input data
Simulation projections were made to assess the ability of the model to forecast
BMI. The bounds on childbearing age range adapted for the population-level model are
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age 15 to 44 years. The starting population consisted of 10,000 women ages zero to 44
years, however, average BMI was only recorded for women of childbearing age (i.e. age
15 to 44 years). Incorporating these individuals into the simulation at baseline ensures
that individuals will reach age 15 on an annual basis. NCHS natality files [CDC5] to
estimate pregnancies and US life tables [CDC6] to estimate mortality allowed us to
capture changes in age distribution of the US population over time. Model projections
were made after zero years, 10 years, 20 years, and 28 years, with age structure
representing the US population in 1980, 1990, 2000, and 2008, respectively. The
regression analysis provided two key input measures for the BMI sub-module in the
simulation: (1) age-specific baseline BMI values, and (2) age-specific change in BMI.
Since there is an overlap in the slopes for certain ages, baseline BMI and updates to BMI
for women were taken as the average of estimates from the regression analysis (refer to
Section 3.2 for explanation). The individual‘s baseline BMI was assumed to be normally
distributed (Table B.1 in the appendix). Table B.2 provides the BMI updates (annual
change in BMI) used in the simulation model, by age and race; these are also assumed to
be normally distributed.
3.4.2 Simulation projections
Projections for zero years represent our underlying population of 1980. Baseline
BMI was used to make projections independent of the individual‘s birth year representing
the population in 1980. Age-specific baseline BMI was assigned to individuals in the
starting population and statistics were collected for average BMI with no time elapsing in
the simulation. To further test the model, projections for average BMI were made over
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time using age-specific baseline BMI and age-specific BMI updates independent of the
individual‘s birth year. Average BMI was projected over time to provide estimates for the
years 1990, 2000, and 2008. The results for all model projections were reported in terms
of age cohort percentages average BMI according to age cohort (age 15 to 19 years, age
20 to 24 years, age 25 to 29 years, age 30 to 34 years, age 35 to 39 years, age 40 to 44
years, and age 15 to 44 years). We implemented common random numbers (CRN) for
three parameters: (1) baseline age distribution, (2) baseline BMI, and (3) annual change
in BMI.
The half-width of average BMI was assessed to determine a sufficient number of
replications [Law, 2007]. The 95 percent confidence interval half-width was pre-specified
to be no larger than 0.15 kg/m2. Fifteen replications led to a sufficiently small half-width
confidence interval for the output measure average BMI for all model scenarios.
Increasing the number of replications did not produce smaller confidence intervals.
3.4.3 Simulation validation
We present two methods for validating our simulation model: (1) validation of
population age distribution, and (2) validation of average BMI estimates. Method one
compares the percentage age distribution of the US Census to our simulated age structure
for 1980, 1990, 2000, and 2008. We consider age structure to be an important validation
criterion because other performance measures (such as BMI) are influenced by the age
attribute. Age structure results for white women are provided in Table 3.4.
Referencing Table 3.4, we validate our1980 and 1990 age percentage estimates
across all age cohorts with 95% confidence interval half-widths in the range of 0.19% to
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0.36%. In 2000, the difference in mean percentage of women ages 25 to 29 and 30 to 35
is very low (0.02% and 0.04%, respectively). This is substantial because women of these
ages are more likely to get pregnant and will therefore have a greater influence on the
population age structure in future generations. Women ages 15 to 19 and 40 to 44
maintain the lowest birth rates and will in turn have less affect on the overall population
structure. Options for improving our simulation projections follow.
First, some input parameters did not assume standard errors, including the natality
data and the mortality estimates. We could build a probability distribution around these
input measures and conduct sensitivity analysis. Second, we could update mortality rates
every year. Age-adjusted death rates in the US have experienced an overall downward
trend [CRS, 2006] since 1980. Older individuals have higher risk of death and reducing
the number of individuals age 40 to 44 will help iron out the distribution and shift the
percentage towards age 15 to 19. Third, we do not assess variability in the Census
estimates. Error and undercount of 44.2 million in the Census 2000 count was reported by
the Accuracy and Coverage Evaluation (A.C.E.) [Census1]. The net undercount for nonHispanic whites was 0.6%. An error of 0.51% and 0.10% for age cohorts 15 to 19 and 40
to 44 respectively in the Census age distribution would validate our simulation.
For 2008 Census age characteristics we note that the percentages are based on
Census 2000 numbers. Population projections of the US for 2008 were based on
assumptions of births, deaths, and immigration [Census2]. Therefore, we have more
confidence in our projections because our numbers are based on actual natality data
between 2000 and 2008.
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Table 3.4: Comparison of the Census and simulation age distributions for white women.
1980
1990
Age
Cohorts
Census (%)
Simulation (%)
Census (%)
Simulation (%)
15 - 19
19.38
19.39 (0.36)
14.17
14.12 (0.24)
20 - 24
20.04
20.00 (0.19)
15.56
15.57 (0.24)
25 - 29
18.53
18.43 (0.22)
18.00
18.22 (0.30)
30 - 34
16.96
17.15 (0.27)
18.87
18.77 (0.24)
35 - 39
13.65
13.65 (0.19)
17.51
17.29 (0.23)
40 - 44
11.44
11.38 (0.26)
15.88
16.03 (0.25)
2000
2008
Age
Cohorts
Census (%)
Simulation (%)
Census (%)
Simulation (%)
15 - 19
15.50
14.70 (0.30)
16.82
16.65 (0.20)
20 - 24
14.40
14.57 (0.22)
16.57
15.86 (0.31)
25 - 29
15.00
15.01 (0.27)
16.66
16.26 (0.29)
30 - 34
16.51
16.55 (0.29)
15.42
15.25 (0.30)
35 - 39
19.13
19.35 (0.28)
16.83
17.19 (0.25)
40 - 44
19.46
19.82 (0.26)
17.69
18.79 (0.27)
Note: Values in parentheses are 95% CI half-widths.

In method two, model validation is achieved when the simulation reproduces
actual average BMI for the starting cohort (1980 projections) and our hypothetical
population over time (1990, 2000, and 2008 projections). For all years we consider our
unadjusted average BMI projections to be the comparison group (representing actual
population BMI). In Section 3.3 we statistically validated 1980 unadjusted BMI
projections against average BMI estimates obtained from the NHANES I and II dataset.
Simulation projections and unadjusted BMI projections (obtained using the regression
estimates) are compared by age cohort. Average BMI results for white women are
summarized in Table 3.5.
Refer to Table 3.5 for a comparison of average BMI unadjusted and simulation
projections. In 1980 and 1990 we are 99% confident that we capture the true population
average BMI. For 2000, simulation projections of average BMI validate for all age
cohorts except 35 to 39. More importantly average BMI of the overall population (age 15
to 44 years) validates in comparison to unadjusted BMI projections. Average BMI of the
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simulated population is driven by the projections of age structure in the simulation. We
believe that although our 2000 estimates do not capture the actual estimate from the
Census 2000 for age cohorts 15 to 19 and 40 to 44, if we model random variation in some
of the input measures (e.g. birth rates, death rates) then our projections will capture the
true value. In 2008, all age cohorts validate for the performance measure average BMI.
Table 3.5: Average BMI unadjusted and simulation projections for white women.
1980
1990
Age
Unadjusted
Simulation
Unadjusted
Simulation
Cohorts
Projections
Projections
Projections
Projections
15 - 19
21.94 (0.11)
21.96 (0.07)
21.94 (0.11)
21.84 (0.08)
20 - 24
22.67 (0.09)
22.70 (0.05)
22.70 (0.08)
22.63 (0.08)
25 - 29
23.40 (0.09)
23.45 (0.13)
23.46 (0.09)
23.49 (0.09)
30 - 34
24.23 (0.11)
24.17 (0.11)
24.15 (0.14)
24.19 (0.05)
35 - 39
24.61 (0.13)
24.70 (0.13)
24.64 (0.12)
24.87 (0.13)
40 - 44
25.17 (0.14)
25.17 (0.12)
25.20 (0.16)
25.44 (0.12)
15 - 44
23.48 (0.04)
23.50 (0.05)
23.75 (0.04)
23.81 (0.04)
2000
2008
Age
Unadjusted
Simulation
Unadjusted
Simulation
Cohorts
Projections
Projections
Projections
Projections
15 - 19
21.89 (0.11)
21.85 (0.08)
21.90 (0.12)
21.87 (0.09)
20 - 24
22.74 (0.09)
22.63 (0.09)
22.73 (0.07)
22.61 (0.08)
25 - 29
23.47 (0.11)
23.38 (0.09)
23.43 (0.11)
23.42 (0.08)
30 - 34
24.14 (0.13)
24.14 (0.11)
24.14 (0.17)
24.14 (0.09)
35 - 39
24.63 (0.11)
24.87 (0.11)
24.65 (0.11)
24.76 (0.09)
40 - 44
25.21 (0.16)
25.42 (0.07)
25.20 (0.16)
25.40 (0.07)
15 - 44
23.80 (0.05)
23.86 (0.04)
23.69 (0.05)
23.74 (0.04)
Note: Values in parentheses are 99% CI half-widths.

3.4.4 Sensitivity analysis
We performed sensitivity analysis on the BMI updates for white individuals age
32 to 37 years due to the large difference in the slopes for this age range obtained from
the regression analysis. Five different scenarios were tested for years 1980, 1990, 2000,
and 2008. The base case scenario (scenario one), was the average of the slopes for birth
year cohorts 1940 to 1949, 1935 to 1939, and 1930 to 1934. Scenario two involved
averaging the points from birth year cohort 1935 to 1939 and 1930 to 1934. Scenario
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three involved using the slope for birth year cohort 1940 to 1949. BMI updates for
scenario four involved taking the average of scenarios one and two, and BMI updates for
scenario five involved taking the average of scenarios one and three. The sensitivity
analysis showed that average BMI was not sensitive to the BMI updates for individuals
age 32 to 37 years. Tables A.3 and A.4 in the appendix show the input parameters (i.e.
baseline BMI and BMI updates, respectively) used in the sensitivity analysis. Results of
the sensitivity analysis are provided in Table B.5 in the appendix.
3.5

Discussion
The unadjusted projections provide an estimate of the population given that the

rate of change in average BMI of white and black women of childbearing age in the
1980s had remained the same between 1980 and 2008. In the unadjusted projections we
observe similar trends in average BMI for white and black women. In the unadjusted
projections average BMI of both black and white women of childbearing age increases
from 1980 to 1990 (a change in average BMI of 0.43 kg/m2 for white women and 0.27
kg/m2 for black women) and again slightly from 1990 to 2000 (white women experienced
a change in BMI of 0.05 kg/m2 and black women experienced a change in BMI of 0.13
kg/m2). In the unadjusted projections the biggest change in average BMI occurs between
1980 and 1990 for both racial groups (0.43 kg/m2 for white women and 0.27 kg/m2 for
black women). Average BMI slightly decreases between 2000 and 2008 among both
white and black women of childbearing age (a change in average BMI of -0.11 kg/m2 for
white women and -0.14 kg/m2 for black women).
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The 95 percent confidence intervals in Figure 3.6 show a statistical difference in
average BMI between the actual population and the projected population for years 1990,
2000, and 2008 for white and black women of childbearing age. The difference in
average BMI each year is larger for black women compared to white women. For
example, in 1990 actual average BMI of white women of childbearing age (i.e. obtained
from the NHANES III data set) is 24.82 kg/m2 and predicted average BMI is 23.75
kg/m2, a difference of 1.07 kg/m2. The difference in actual average BMI (27.78 kg/m2)
and predicted average BMI (26.02 kg/m2) for black women of childbearing age in 1990 is
1.76 kg/m2. The difference in actual average BMI versus projected BMI is greater among
black women versus white women in 1990, 2000, and 2008.
In terms of health disparities, the results show two key findings. First, NHANES
shows that black women not only started out with higher average BMI (25.80 kg/m2) as
compared to white women (23.62 kg/m2) in 1980, before the onset of the obesity
epidemic, but their weight gain between 1980 and 2008 was also higher. Resulting in an
average BMI of 29.26 kg/m2 (an increase of 3.46 kg/m2 over 28 years) for black women
as compared to 26.68 kg/m2 (an increase of 3.06 kg/m2 over 28 years) for white women
over all ages (15-44). The disparity in average BMI between black and white women of
childbearing increased by 0.4 kg/m2 from 1980 to 2008. Secondly, the unadjusted
projections show that this difference cannot be solely explained by the weight gain trends
that were taking place in 1980; that is, the disparity has worsened. Our unadjusted
projections predict that if weight gain trends from 1980 had prevailed the disparities
between these groups would not have increased, rather the difference in BMI between
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black and white women in 2008 would be 2.32 kg/m2, which is not significantly different
that the disparity seen in 1980.
The results we provide here are fundamentally different than what is currently
available in the literature in that we base our unadjusted projections on the population
previous to the onset of the obesity epidemic. Using cross-sectional data from NHANES I
and II we determine the change in BMI due to age among white and black women of
childbearing age. Based on the baseline population, our unadjusted projections show that
the average BMI among women of childbearing age would be stable from 1980-2008.
Instead, we find (as do many other studies) that the actual weight gain has increased over
time. While the reasons for this could be many, understanding the difference between the
baseline population and the current population is a first and key step to understanding the
potential causes that could be behind the accelerated weight-gain seen over the past two
decades, and that will drive longer term projections.
Lastly, we point out that other studies that make projections on the trends of
diseases (most of these are done with respect to diabetes) begin with prevalence estimates
in 2000 or later. At this point the obesity (and also diabetes) epidemics had already taken
place; resulting in very high estimates. Wang et al. (2008) use NHANES 1976-1980 to
2003-2004 to calculate the average annual increase in the prevalence of obesity and
overweight and apply this using a linear regression model to make projections through
2030, resulting in an estimated 87% of all adult women being overweight or obese. Other
examples of projection studies which begin with data after the onset of the ―diabesity‖
epidemic include: diabetes projections for the US population through 2031 [Mainous et
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al., 2007] and through 2050 [Boyle et al., 2001], obesity projections for South Australia
through 2013 [Dal Grande et al., 2005], and global diabetes projections through 2030
[King et al., 1998]. In this paper we considered the weight gain trends associated with
NHANES I and II (1971-1974 and 1976-1980) and find that these trends would have
resulted in stable average BMI levels compared to actual BMI trends over time.
As discussed in Section 3.4.3 (Tables 3.4 and 3.5), our simulation projections at
baseline, 1990, and 2008 validate statistically for two measures (age structure and
average BMI). In 2000, we validate average BMI across all age cohorts except 35 to 39.
We believe that by incorporating random variation in birth and death estimates and
accounting for Census errors, we can validate our 2000 estimates for age cohort 35 to 39.
We are confident in our simulation projections for one generation of one cohort (white
women of childbearing age). However, we acknowledge that our simulation has
limitations.
In terms of limitations, first, a key limitation is that the Census 2000 data set
contains an enormous amount of errors (many more than the Census 1990) [U.S. Census
Monitoring Board, 2001]. This not only affects simulation projections (in terms of
simulation validation), but also impacts the unadjusted BMI projections over time. Next,
pregnancy probabilities are not subject to random variation. Registered births occurring
in the US are not 100% accurate and may be influenced by non-sampling errors (i.e. the
mother‘s age or race may be mistakenly documented) [CDC10]. Similarly, US life table
errors (i.e. errors in death rates) such as mistakes in recording age on the death certificate
may distort age-adjusted death counts. Under-registration of deaths is not assumed to be
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significant for reasons including burial permit requests, acquirement of insurance
benefits, and estate settlements. Last, reasons other than births or deaths shape the
population (e.g. immigration) [Bell and Miller, 2005].
We are currently making attempts to address the limitations of our data sources.
Sensitivity analysis will assess how robust the simulation is to these input measures. With
the release of Census 2010 estimates our projections will be updated and age
characteristics validated against actual Census estimates (rather than Census projections
of 2008).
Future research will be conducted to test different models for attributing increased
risk in weight-gain over time. Various epidemiologic models for increased risk will be
evaluated to determine which model projections most closely resemble the actual data of
the US population. The results will be used to predict effects due to the obese intrauterine
environment. Once the risk factor is established, projections will be made regarding
weight-gain and the prevalence of obesity over a longer time period (e.g. 100 years).
These projections will demonstrate the extent to which these affects may be exacerbated
over time. We seek to quantify the impact of intrauterine exposure to maternal obesity
across multiple generations in different race/ethnicity groups at the population level
thereby allowing estimations to be made regarding the extent to which intrauterine
programming could be influencing health disparities. This research will aid decision
makers in recognizing the impact of preventative-care initiatives as well as in the
evaluation of possible alternatives.
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CHAPTER FOUR
A DISCRETE-EVENT SIMULATION MODEL TO ESTIMATE HEALTH AND
ECONOMIC OUTCOMES OF SMOKING CESSATION TREATMENTS

This chapter focuses on the development and verification of a DES model to
estimate health and economic outcomes associated with smoking cessation interventions.
4.1

Model Introduction
According to the US Surgeon General, active cigarette smoking remains a major

public health problem, despite numerous health warnings, FDA regulation, highly
publicized litigation efforts against major tobacco companies, and a bevy of accumulated
epidemiologic evidence chronicling the health risks of smoking [US Department of
Health and Human Services, 2004]. Countless studies have demonstrated that ―smoking
is the single greatest cause of avoidable morbidity and mortality in the United States‖
[US Department of Health and Human Services, 2004]. However, smoking prevalence
remains quite high, and despite the fact that 70% of smokers want to quit, long-term
smokers have considerable difficulty breaking the habit and overcoming addiction to
nicotine [CDC11].
Multiple smoking cessation therapies and interventions have been developed
since the early 1960s to aid smokers who desire to quit; however, more than 46 million
adults in the United States continue to smoke cigarettes and even with pharmacologic
intervention, recidivism remains extremely high [CDC12]. Smokers who desire to quit
often try numerous unsuccessful pharmacotherapies, which may be costly and generally
ineffective, resulting in economic hardship and feelings of failure or guilt [Ranney et al.,
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2006]. Considering the significant health and economic burden of smoking and the
unavailability of a tried and true ―magic bullet‖ for smoking cessation, comparative
effectiveness studies are needed to compare different smoking cessation options and
corresponding outcomes.
Although the effectiveness of smoking cessation therapies has been low, smoking
cessation, when successful, has been shown to be highly cost-effective. Studies have
compared placebo to different pharmacologic interventions for smoking cessation
[Jackson et al., 2007; Neilson and Fiore, 2000]. Studies have compared the nicotine patch
to smoking-cessation counseling [McGhan and Smith, 1996; Fiscella and Franks, 1996;
Cromwell et al., 1997] and nicotine gum to smoking-cessation counseling [Cromwell et
al., 1997]. Gilbert et al. (2004) included five pharmacological treatments including
nicotine gum, patch, nasal spray, inhaler and bupropion in which the control group
received smoking-cessation counseling and the treatment cohort was given counseling in
addition to pharmacological treatment. Howard et al. (2008) compared varenicline,
bupropion, nicotine replacement therapy, and unaided smoking cessation where the main
objective of the study was to assess the cost-effectiveness of varenicline.
Cost-benefit studies of smoking cessation therapies that require decision making
under uncertainty have employed decision tree analysis [Fiscella and Franks, 1996;
McGhan and Smith, 1996; Nielsen and Fiore, 2000; Jackson et al., 2007] and Markov
structures [Orme et al., 2001 (in Reifsnider, 2011); Gilbert et al., 2004; Gilbert et al.,
2006 (in Reifsnider, 2011); Howard et al., 2008] to provide a simplified description of a
complicated clinical problem which aids decision makers in understanding the risks and
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benefits of various clinical options. To our knowledge, discrete-event simulation (DES)
has not been employed to compare therapeutic options for smoking cessation and related
health outcomes. Because individuals have varying levels of nicotine dependence and
smoking intensity, and because of significant heterogeneity in treatment response, we
believe the DES approach is a potentially more meaningful way to conceptualize the
problem of smoking cessation.
The remaining chapter is organized as follows. In §5.2, a description of the data
and assumptions of the simulation is provided. In §5.3, measures of health and economic
evaluation are described and the simulation verification is described in §5.4. The chapter
is concluded with §5.5, in which we discuss limitations of the model and future research
directions.
4.2

Model Assumptions and Data

4.2.1 Simulation structure
We developed a DES model using Arena 13.5 software. The simulation consists
of four main modules: creation of smokers, smoking cessation treatment, disease
progression, and accounting (Figure 5.1). The accounting sub-module periodically
updates patient attributes and population statistics. In terms of the progression of the
model, first, individuals are created and all individuals are assumed to be smokers. Next,
the smoker begins treatment and the model evaluates, according to trial-based efficacy
evidence, whether or not the treatment was successful. If treatment is successfully
completed, then the patient enters the non-smoker state; otherwise, the patient remains a
smoker with no additional attempts at treatment. A periodic update of patient disease
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progression, aggregate quality adjusted life-years (QALY), health utilities, costs, age,
mortality, and statistical accumulation occurs annually regardless of the patient‘s
smoking status. A detailed description of the operations of each sub-module follows.

Figure 4.1: High-level schematic of simulation flow.

4.2.2 Creation of smokers
The creation module creates smokers and allows the administrator to input
background demographic and clinical information of the underlying population. A
discrete number of patients enter the system representing a single cohort sampled from a
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chosen population. The initial cohort consists of 10,000 individuals made up of males and
females ages 18 to 70 years, assigned according to 2008 US Census population tables
[Census2] and US smoking prevalence estimates taken from the 2008 National Health
Interview Survey (NHIS) [NCHS, Table 4.1]. Refer to Appendix table D.1 for the
calculated distribution of smokers. No additional entities enter the simulation; however,
individuals may exit the model due to death. Demographic and clinical attributes are
assigned to each individual in the simulation at baseline including gender, age, and
quality of life (refer to Section 4.3.1). Quality of life numbers were drawn from the
literature [Fiscella and Franks, 1996; Stewart et al, 2009 (in Reifsnider, 2011)] and are
assigned based on individual demographic attributes. For example, gender and age are
assigned independently but utilities or quality of life associated with certain health states
depend upon the gender and age attributes. Probabilities of transitioning between health
states are also dependent upon these background attributes. All patients enter the model
as smokers and are considered ―healthy‖ at baseline. A healthy patient is characterized as
a smoker with no serious smoking-related co-morbidities of interest [i.e., lung cancer,
chronic obstructive pulmonary disease (COPD), stroke, coronary heart disease (CHD)].
Table 4.1: Smoking prevalence among adults in the US.
Age Group
Male
Female
18 - 44

0.254

0.203

45 - 64
65+

0.246
0.106

0.205
0.082

4.2.3 Smoking cessation treatment
Smoking cessation alternatives considered in this model include nicotine
replacement treatment (NRT) interventions, bupropion, varenicline, and non-
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pharmacologic-assisted cessation. The four NRT products considered in this model
(patch, inhalator, gum, and nasal spray) are known to have different costs, adherence, and
outcomes; hence, average statistics across the four NRT products are input into the
simulation to represent the NRT treatment option. We run the simulation in five
scenarios, one scenario for each of the four strategies (NRT, bupropion, varenicline, and
non-pharmacologic-assisted) and one for no treatment.
Upon entry into the simulation, 100 percent of smokers make one attempt at
treatment. Duration of active treatment is 12 weeks for all interventions of interest
[AMA, 2000] and individuals are assumed to adhere to treatment for the full duration.
Intervention-specific efficacy rates are applied at the end of year one at which time
individuals either successfully quit smoking or remain smokers. Reported efficacy rates
for smoking cessation are highly variable, therefore we performed a meta-analysis of the
efficacy of smoking cessation strategies to obtain an estimate of the summary effect size
across studies. A review of the medical literature identified 6 studies for NRT, 6 studies
for bupropion, 5 studies for varenicline, and 4 studies for non-pharmacologic-assisted
(Table 4.2). Results across studies per strategy were combined to provide a single pooled
result quantifying how much each intervention is beneficial. The mid-point value was
considered our baseline probability of treatment success.
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Table 4.2: Efficacy rates (defined as treatment-specific, CO2-verified, continuous abstinence rate over a
one-year time period, i.e. during trial follow-up).
Cessation alternative
Proportion Abstinent
Reference*
Aubin et al, 2008; Bohadana et al, 2000; Jorenby et al,
NRT
0.13 (0.06-0.20)
1999; Nielson and Fiore, 2000; Silagy et al, 2002;
Raw, McNeill, and West, 1998
Jorenby et al, 2006; Fossati et al, 2007; Jorenby et al,
Bupropion
0.225 (0.15-0.30)
1999; Nides et al, 2008; Silagy et al, 2002; Gonzales
et al, 2006
Niaura et al, 2008; Garrison et al, 2008; Rigotti et al,
Varenicline
0.215 (0.18-0.25)
2010; Gonzales et al, 2006; Nides et al, 2008
Non-pharmacologicHughes et al, 2004; Raw, McNeill, and West, 1998;
0.05 (0.03-0.07)
assisted
Foulds et al, 2004; Fiore, 2000
NRT = Nicotine Replacement Therapy
* Refer to Reifsnider (2011).

Successful quitters are referred to as former smokers and are at risk of relapse
(refer to Section 4.2.5 for more explanation) as they move through the disease
progression and accounting modules each year. Individuals who did not successfully quit
smoking loop through the disease progression and accounting modules each year until
death.
4.2.4 Disease progression
Although smoking is a risk factor for numerous non-communicable diseases, we
chose to focus on lung cancer, chronic obstructive pulmonary disease (COPD), stroke,
and coronary heart disease (CHD), for two reasons. First, these four diseases represent
significant epidemiologic and economic burdens to American society [US DHHS, 2004]
and second, good data exist on the probabilities and outcomes for these disease states in a
smoking population. Diseases are either present/absent with the possibility of acute
exacerbation or improvements in condition. Individuals may develop one or more
smoking-related condition. Estimates of lung cancer, COPD, stroke, and CHD were
determined by the literature and considered to be dependent upon demographic attributes
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(age and gender) and the individual‘s smoking status - current smoker or former smoker.
The disease progression module updates the individual‘s health state annually. The health
state not only takes account of diagnoses of chronic conditions (and corresponding health
utilities), but also considers incident complications associated with each co-morbidity,
such as a COPD exacerbation.
An individual may develop different levels of COPD (mild, moderate, or severe).
In the absence of good data about COPD transitions between mild, moderate, and severe
disease, we assumed that people diagnosed with COPD were diagnosed with mild,
moderate, and severe disease according to proportions in the literature and that they
remained in those ―states‖ until death. Baseline utility values are assigned to individuals
who have COPD (Table 4.9 of Section 4.3.1). Individuals living with COPD are at risk of
COPD exacerbations (minor or major). Refer to Table 5.3 for estimates of COPD.
Annual incidence of COPD exacerbation is modeled for each COPD level by
applying the binomial probability distribution. For example, the exacerbation rate per
annum for mild disease of 0.79 is converted to an annual probability of 0.5462 [1-e(0.79)].
We assume a maximum of 4 possible COPD exacerbations annually. Since the expected
value, E(x), of a binomial distributed random variable is the product of the number of
trials [(n); 4] and the proportion of success [(p), COPD exacerbation] we compute the
likelihood of independent COPD exacerbations to be 0.1366. The probability table is
given in Table D.2 of the Appendix. Next, we determine how many major exacerbations
occurred using the binomial distribution formula and given the annual number of COPD
exacerbations and the percentage of minor exacerbations (refer to Appendix Table D.3
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for computed probabilities). COPD utility values are weighted based on the number and
type of COPD exacerbations. COPD exacerbations lower the baseline COPD utility
values for a period of 3 months.
Table 4.3: Lifetime probability of developing COPD, by gender and smoking status.
Risk of developing COPDa

Cumulative/lifetime probability of COPD**

Current smoker
Male
0.32
Female
0.32
Former smoker/non-smoker*
Male
0.13 (0.12-0.14)
Female
0.13 (0.12-0.14)
Severity of COPDb
Proportion in each severity category
Mild disease
70.34% (68-73%)
Moderate disease
19.33% (19-20%)
Severe disease
10.33% (8-13%)
COPD exacerbationc
Exacerbation frequency (per annum)
Mild disease
0.79
Moderate disease
1.22
Severe disease
1.47
Minor exacerbationc
Mild disease
94%
Moderate disease
93%
Severe disease
90%
COPD = chronic obstructive pulmonary disease
*We assume a former smoker carries the same risk as a non-smoker
** Lifetime probability calculated by converting lifetime rate to annual probability using sexspecific life expectancy tables for smokers at 50 years; former smokers group denominator
calculated using the average LE between current smokers and general population
(a) Reference is Pelkonen et al. (2008), (b) Reference is Wilson, Devine, and So (2000), (c)
Reference is Spencer et al. (2005) [(refer to Reifsnider (2011)]

Individuals are at risk of multiple stroke exacerbations over their lifetime.
Estimates of stroke are provided in Table 4.4. Stroke utility values are weighted to reflect
the two month period following the first stroke event. Subsequent strokes result in a
permanent decrement in the stroke utility value. Utility values for stroke are shown in
Table 4.9.
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Table 4.4: Age-standardized rate of stroke per 100,000 person-years, by gender and smoking status.
Current smoker
Former smoker*
Male
656.6
496.4
Female
565.6
506.7
* We assume a former smoker carries the same risk as a
non-smoker

Table 4.5: Risk of lung cancer, by smoking status.*
Current smoker**
Incidence rate
Age < 55 years***
0.0000
Age 55-64 years
6.0000
Age 65-74 years
7.5000
Age 75-84 years
8.1667
Age > 84 years
8.1667
* Incidence rate of lung cancer among nonsmokers,
in person years (100,000)
**Current smoker = averaged 1pack/day and 2
packs/day for 25 years, 40 years, and 50 years
***We assume that individuals less than 55 years of
age do not develop lung cancer
Former smoker: relative risk = 10
Reference: in Reifsnider (2011)
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Table 4.6: Age-specific, ten-year rate of CHD, by gender, age, and smoking status.
Current smoker
Incidence rate
Former smoker*
Incidence rate
Male
Male
Age < 30 years**
0.0000
Age < 30 years**
0.0000
Age 30-34 years
0.0336
Age 30-34 years
0.0200
Age 35-39 years
0.0504
Age 35-39 years
0.0300
Age 40-44 years
0.0672
Age 40-44 years
0.0400
Age 45-49 years
0.0672
Age 45-49 years
0.0400
Age 50-54 years
0.1008
Age 50-54 years
0.0600
Age 55-59 years
0.1176
Age 55-59 years
0.0700
Age 60-64 years
0.1512
Age 60-64 years
0.0900
Age 65-69 years
0.1848
Age 65-69 years
0.1100
Age 70-74 years
0.2352
Age 70 years
0.1400
Age > 74 years**
0.2352
Age > 74 years**
0.1400
Female
Female
Age < 30 years**
0.0000
Age < 30 years**
0.0000
Age 30-34 years
0.0074
Age 30-34 years
0.0050
Age 35-39 years
0.0147
Age 35-39 years
0.0100
Age 40-44 years
0.0294
Age 40-44 years
0.0200
Age 45-49 years
0.0441
Age 45-49 years
0.0300
Age 50-54 years
0.0735
Age 50-54 years
0.0500
Age 55-59 years
0.1029
Age 55-59 years
0.0700
Age 60-64 years
0.1176
Age 60-64 years
0.0800
Age 65-69 years
0.1176
Age 65-69 years
0.0800
Age 70-74 years
0.1176
Age 70-74 years
0.0800
Age > 74 years**
0.1176
Age > 74 years**
0.0800
CHD = coronary heart disease
* We assume a former smoker carries the same risk as a non-smoker
**We assume that individuals less than 30 years of age do not develop CHD
***We assume the risk for CHD in the oldest age group is equal to the next closest age group
Reference: in Reifsnider (2011)

Improvements in condition are taken into account by allowing the health state
utility to be modified for post-exacerbation improvements over time, which is relevant
for acute events such as stroke and COPD exacerbations. For example, patients who have
suffered a stroke are considered to have a history of stroke, which is an improvement
over the actual stroke event itself, and patients who have suffered more than one stroke
are considered to have a history of multiple strokes. An individual who experiences a
stroke has a corresponding utility of 0.425 for the event itself (in this case, we assume
quality of life is seriously affected for two months) [Wolf et al., 1992 (in Reifsnider,
2011)]. After two months, the individual‘s condition improves but still has an average
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utility considerably worse than perfect health, 0.725, reflecting stroke-related disability
[Howard et al., 2008]. If the same person has an additional stroke, the utility drops
substantially because we assume that multiple strokes lead to significant
disability/morbidity.
Individuals are at risk for disease-specific mortality per annum. We model two
causes of death - disease-specific mortality and all-cause mortality - which allows both
deaths from smoking-related diseases of interest and death from natural causes to be
taken into account. Deaths due to lung cancer, COPD, stroke, and CHD complications are
accrued within the disease progression module. Mortality from all causes is determined in
the accounting module.
Case fatality rates are used to estimate disease-specific risk of mortality (Table
4.7). Case fatality rates are specific to those people who have already been diagnosed
with a disease; that is the proportion of individuals with a disease who die from the
disease during a given time period. Information is not available for smoking statusadjusted case fatality rates. Since the incidence rates for disease have been adjusted by
smoking status, there is no reason to think that once diagnosed with the disease of
interest, smokers should have differential risk of death than non-smokers. So, once
individuals have the disease of interest, we assume their prognosis is similar.
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Table 4.7: Case fatality rates over the time period of interest.
Co-morbidity
Case fatality rate
Reference
CHD
At 1 year
44.5%
MacIntyre et al, 2000
At 5 years
76.5%
At 10 years
87.6%
Stroke (exacerbation)
1 year overall
35% (32-38%)
Nieuwkamp et al, 2009; Feigin et al, 2003
Lung Cancer
At 5 years
85%
Parkin et al, 2002
COPD
After at 1+ major exacerbation
15.6%
Hoogendoorn et al, 2010
CHD = coronary heart disease; COPD = chronic obstructive pulmonary disease

We assume the case fatality rate of CHD and lung cancer to increase linearly over
time. COPD-related death is possible if at least one major exacerbation occurred,
regardless of the level of disease (mild, moderate, or severe). A case fatality rate of 35
percent is assumed if an individual experiences at least one stroke annually.
4.2.5 Accounting module
The accounting module serves several purposes. First, patient attributes including
age and health utilities and QALYs (refer to Section 4.3.1) are periodically updated.
Next, non-disease-specific all-cause mortality is determined in the accounting module
and recidivism after successful treatment. Outcomes are measured to draw insights into
the long-term health and economic effects of smoking cessation.
We used life tables from the Centers for Disease Control and Prevention
(CDC)/National Center for Health Statistics (NCHS) on age-specific, gender-specific, allcause mortality in the American population [Rogers and Powell-Griner, 1991 (in
Reifsnider, 2011)] to determine non-disease-specific death. The CDC/NCHS data on allcause mortality in the American population includes deaths from diseases we are
interested in tracking in the model (i.e. lung cancer, COPD, stroke, CHD) but will include
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―healthy‖ nonsmokers as a potential balance. We expect the incidence of death due to
lung cancer, COPD, stroke, and heart disease to be lower in the healthy, nonsmoking
population, which may help counter some of the possible/theoretical double counting of
deaths in the model. It is unclear how to fully separate these risks at this time since we do
not have a measure for ―all-cause mortality, excluding deaths from lung cancer, COPD,
stroke, and heart disease‖.
Using the published literature, we estimated the probability of recidivism after
successful treatment (Table 4.8). Former, successfully treated, smokers can be assumed
to relapse according to annual probability, which is based upon the total time abstinent;
that is to say, the longer a former smoker has remained abstinent from smoking, the more
likely he/she is to continue to refrain. There is no time period after which a former
smoker has no risk of relapse. Gilpin, Pierce, and Farkas (1997; in Reifsnider, 2011)
established in their cohort study of 1449 former smokers that even after 10 years of
abstinence from smoking, there was no time period after which former smokers had no
risk of relapse. Therefore, although the risk of relapse diminishes significantly over time,
no former smoker is ever completely immune to the potential for relapse. Recidivism
rates depend on the number of years abstinent and are not treatment specific.
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Table 4.8: Probability of recidivism after 12 months continuous abstinence (defined as non-treatmentspecific, prolonged abstinence beyond 12 months).
Proportion relapsed
(among those who
Time period
Reference*
were continuously
abstinent at 12 mos)
Hughes et al, 2008; Gilpin, Pierce and Farkas, 1997; Wetter et al,
Years 1-2
0.165 (0.09-0.24)
2004
Years 2-5
0.097 (0.024-0.17)
Wetter et al, 2004; Hughes et al, 2008; Krall et al, 2002
Years 5-10
0.0425 (0.005-0.08)
Wetter et al, 2004; Krall et al, 2002; Hughes et al, 2008
Years 10+
0.0055 (0.001-0.01)
Cromwell et al, 1997; Krall et al, 2002
* Refer to Reifsnider (2011)

In addition to updating patient characteristics, the model generates statistics on
smoking prevalence, incidence of relapse, average QALYs gained due to an intervention
(i.e. effectiveness), death from smoking-related conditions, smoking cessation treatment
costs, and costs associated with managing a smoking-related chronic disease or
exacerbation (refer to Section 4.3.2 for cost information). Epidemiologic and economic
outcomes can be viewed annually or cumulatively.
4.3

Health and economic measures

4.3.1 Quality of life
Quality-adjusted life year (QALY) is a measure of disease burden on both quality
and quantity of life and can account for morbidity and mortality on quality of life. A
QALY can be thought of as a year of life quantified by the quality of life or value of
living in a particular state of health. The quality of life element is measured in terms of
health utilities. The basic concept behind a QALY is that the amount of time spent in a
particular health state is weighted by a health state utility score which attempts to reduce
multi-dimensional health outcomes to a single representation or measure of health. Health
state utility scores represent the severity of a disease relative to perfect health and are
scaled between 0 (indicating death) and 1 (indicating perfect health). QALYs provide a
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common measurement to compare treatment options in terms of health related quality of
life by quantifying how much someone‘s life could be extended or improved by an
intervention.
Health state utilities, as a measure of quality of life associated with particular
conditions, were drawn from the peer-reviewed literature (Table 4.9). We incorporated
gender- and age-specific utility values, where possible. We assumed that smokers in good
health had a slightly lower utility than former smokers in good health and that quality of
life decreased with age, in accordance with the literature (Table 4.10).
Co-morbidity
CHD

Table 4.9: Health state utility values for smoking-related co-morbidity.
Utility
Reference*
0.645
Gold et al, 1998; Sullivan and
(0.50-0.79)
Ghushchyan, 2006; Barton et al, 2008

Stroke
Months 0-2 after first stroke event

0.425
(0.33-0.52)

Months 2+ after first stroke event
(improvement after rehabilitation)

0.725
(0.55-0.90)

After subsequent/second stroke
(lasting disability)

0.24
(0.15-0.33)
0.50
(0.39-0.61)

Lung Cancer

Wolf et al, 1992; Hoerger et al, 2004;
Sturm et al, 2002; Tengs and Lin, 2003
Tengs et al, 2001, 2003; Duncan et al,
2000; Howard et al, 2008; Barton et al,
2008; Mittmann et al, 1999; Tengs and
Lin, 2003
Howard et al, 2008; Tengs and Lin,
2003
Gold et al, 1998; Trippoli et al, 2001

COPD
Baseline mild disease
Baseline moderate disease
Baseline severe disease

0.82
(0.81-0.83)
0.775
(0.72-0.83)
0.70
(0.67-0.73)
0.72

Spencer et al, 2005; Rutten-van Molken
et al, 2006
Spencer et al, 2005; Rutten-van Molken
et al, 2006
Spencer et al, 2005; Rutten-van Molken
et al, 2006
Spencer et al, 2005

Minor exacerbation (3 mos) mild disease
Minor exacerbation (3 mos) moderate
0.658
Spencer et al, 2005
disease
Minor exacerbation (3 mos) severe disease 0.475
Spencer et al, 2005
Major exacerbation (3 mos) mild disease
0.52
Spencer et al, 2005
Major exacerbation (3 mos) moderate
0.45
Spencer et al, 2005
disease
Major exacerbation (3 mos) severe disease 0.41
Spencer et al, 2005
CHD = coronary heart disease; COPD = chronic obstructive pulmonary disease
* Refer to Reifsnider (2011)
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Table 4.10: Health state utility values for current and former smokers.
Current smokers
Female utility value
Male utility value
Age 24 and younger*
0.91
0.93
Age 25 - 29
0.89
0.91
Age 30 - 34
0.87
0.88
Age 35 - 39
0.84
0.86
Age 40 - 44
0.82
0.83
Age 45 - 49
0.80
0.81
Age 50 - 54
0.78
0.78
Age 55 - 59
0.76
0.76
Age 60 - 64
0.74
0.74
Age 65 - 69
0.72
0.71
Age 70 and older*
0.70
0.69
Former smokers
Female utility value
Male utility value
Age 24 and younger*
0.94
0.95
Age 25 - 29
0.92
0.93
Age 30 - 34
0.9
0.93
Age 35 - 39
0.89
0.92
Age 40 - 44
0.87
0.9
Age 45 - 49
0.86
0.89
Age 50 - 54
0.84
0.87
Age 55 - 59
0.82
0.85
Age 60 - 64
0.79
0.83
Age 65 - 69
0.77
0.8
Age 70 and older*
0.75
0.78
* Assumption; Note: quality of life expressed as mean, where 1.0 is equal to
optimum health and 0.0 is equal to death
Refer to Reifsnider (2011)

Incorporating concepts from financial analyses and the health state utilities leads
to the development of the QALY equation. A common practice in economic evaluations
is to discount both future costs and benefits. Discounting in the context of economic
evaluations deals with time preference and implies that costs and benefits occurring at
different points in time are valued differently. That is, individuals prefer to enjoy benefits
in the present while postponing any negative effects. For example, taking into account the
opportunity cost of investing now rather than in the future would mean that future costs
must be discounted. Discounts are applied on an annual basis. Expenses sustained during
the first year would not be discounted. Let us assume that a standard annual discount rate
of 3.0 percent is applied for all economic outcomes. Expenses sustained during the
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second year would then be discounted by 3.0 percent which means that these expenses
would be divided by 1.03. Expenses acquired during the third year would be divided by
1.032 and each consecutive year would be discounted by an additional 3.0 percent.
Therefore the discount factor is given by equation (2) where r is the annual discount rate
and t is time in years.
Discount factor =

(4.1)

Similarly, this economic concept of discounting is utilized in health care management.
Annual discount rates are applied to health outcomes to account for the fact that health is
worth more now than later.
Equation (1) was used to calculate the aggregate quality of life-years over the
patient‘s lifetime and is the sum of all QALYs associated with different health states over
the natural lifetime of the patient (i.e. for each year of life in each health state, the
relative/weighted value (utility) of that year in that health state). We define t as the time
in years in which the patient is cycling through the simulation model. The health state
utility during year t is defined by Ut and represents an annual assessment of quality of
life. Ut can be thought of as the ―expense‖ to the patient of living in a certain health state
during year t. We define T as the total number of years the patient cycles through the
simulation model until death, and r is the annual discount rate applied for all economic
and health outcomes. A standard annual discount rate of 3.0 percent was applied for all
economic and health outcomes [Gold et al., 1996]. For example, person A is healthy in
year 1 (utility value = 1), has a stroke in year 2 (utility value = 0.5), goes through
rehabilitation and attains some functional recover in year 3 (utility value = 0.75), and dies
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at the beginning of year 4 (utility value = 0). This person‘s QALY over the 4 year period
of time is 1 + 0.485437 + 0.706947 + 0 = 2.19238.
(4.2)
4.3.2

Costs
We use 2010 costs of co-morbidities and smoking cessation products. Treatment

is paid for upfront; if a patient dies during year one then the total cost of treatment has
been incurred. Costs of pharmacological interventions are summarized in Table 4.11.
Zero cost is associated with the non-pharmacologic-assisted option. Cost for each comorbidity and event costs (2010 values, $US) were derived from multiple sources and are
shown in Table 4.12.
Table 4.11: Costs (2010 values, $US) of pharmacological treatment.
Annual cost in
Treatment
Reference
2010 US$
NRT
$485.29
Howard et al, 2008
Bupropion
$348.69
Red Book: Pharmacy‘s
Fundamental Reference 2010
Varenicline
$430.53
Red Book: Pharmacy‘s
Fundamental Reference 2010
Non-pharmacologic-assisted
$0.00
NRT = Nicotine Replacement Therapy
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Table 4.12: Cost (2010 values, $US) of treating co-morbidity and event costs.
Annual cost in
Co-morbidity/Event
Reference*
2010 $US
Cost of treating CHD
First year after diagnosis
$8,930
Tsevat et al, 2001;
Howard et al, 2008
Subsequent years after diagnosis
$4,239
Tsevat et al, 2001;
Howard et al, 2008
Cost of treating stroke
First year after diagnosis
$41,391
Taylor et al, 1996
Subsequent years after diagnosis
$17,688
Taylor et al, 1996
Phase-specific cost of treating lung cancer
Initial treatment phase (5.7 mos)
$13,759
Kuticova et al, 2005
Secondary treatment phase (7.4 mos)
$4,468
Kuticova et al, 2005
Terminal treatment phase (5.6 mos)
$11,249
Kuticova et al, 2005
% receiving terminal treatment only (no initial
9%
treatment)
Kuticova et al, 2005
% receiving secondary treatment after failing initial
29%
treatment
Kuticova et al, 2005
% receiving terminal treatment immediately after failing 27%
initial treatment
Kuticova et al, 2005
Annual cost of treating COPD
$5,369
Halpern et al, 2003
CHD = coronary heart disease; COPD = chronic obstructive pulmonary disease
* Refer to Reifsnider (2011)

We seek to assess the gains in health relative to the costs of different health
interventions, therefore annual discounting was also applied to total costs (i.e. treatment
cost, costs of co-morbidity, co-morbidity event costs). Discounting of costs assumes that
a dollar in the present is worth more than a dollar in the future. Let

represent the total

cost incurred during year t. Equation (2) was used to calculate the sum of all costs over
the lifetime of the patient.
(4.3)
4.4

Model Accreditation
Integrated practices were employed during the model development process to

ensure the credibility of the model. First, the assumptions underlying the conceptual
model were established based upon consultations that took place with clinicians during
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the formative stages of the simulation model. Additionally, discussions with clinicians
established that the model structure and causal relationships reasonably represent the
actual system. During the implementation stages of the model, testing verified that the
logic and mathematical correlations behind the simulation model operate according to
model specifications. In addition to the interactions of the aggregate model, each submodule was evaluated to determine the appropriate level of detail. Next, input data and
performance of output measures were assessed during the modeling building process to
substantiate model accuracy in accordance with the models intended purpose. Clinicians
performed both qualitative and quantitative analysis of output behaviors to confirm that
the predicted values were of reasonable magnitude.
4.5

Conclusions
We developed a discrete event simulation model to explore comparative

effectiveness of various smoking cessation options available to smokers in a US
population. Recognizing that smoking has significant health impacts in terms of
morbidity and mortality from smoking-related diseases, this model expands upon the
current literature by (1) simultaneously comparing multiple pharmacologic and nonpharmacologic options for smoking cessation, which many clinical trials have failed to
do, and (2) using an innovative modeling approach, discrete event simulation, which
allows for individual-level variation in smoking intensity, risk, treatment adherence, and
relapse to be taken into account in assessing the effectiveness of various smoking
cessation strategies.
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In terms of limitations and ongoing research needs, we identified a need for better
smoking-related disease risk data by pack-years. Much of the available data on health
risks from smoking is reported according to general categories of ―never smoked‖,
―former smoker‖, ―light current smoker‖ and ―heavy current smoker‖, the latter two of
which are not well defined and not well validated. Additionally, recognizing that smoking
status and disease risk are both heavily dependent on socioeconomic and sociodemographic characteristics, it would be useful in future models to incorporate additional
information about race/ethnicity, education, income/wealth, and occupation, provided
good data are available. These individual-level factors have been shown in the literature
to be important confounders or mediators affecting the causal relationship between
smoking and disease incidence. Another limitation of this work is that we did not
consider geographic or environmental factors related to smoking and disease risk; future
work could compare risk of recidivism based on location (e.g., different states, urban
versus rural) or environment (e.g., occupational environment, including other
environmental exposures such as asbestos or atmospheric pollution).
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CHAPTER FIVE
ESTIMATING COST-EFFECTIVENESS OF ALTERNATVE SMOKING
CESSATION STRATEGIES

The purpose of this chapter is to evaluate and analyze the results of the simulation
model presented in Chapter 4. We introduce our key statistic for assessing costeffectiveness. A detailed comparative and sensitivity analysis of smoking cessation
alternatives is presented and we discuss potential health policy impacts associated with
the predictions of the model.
5.1

Incremental cost-effectiveness ratio
In this section we introduce analytical methods for comparing alternative

treatment strategies. The incremental cost-effectiveness ratio (ICER) is a standard
measure used to compare the cost-effectiveness of two treatment options. ICERs provide
a common unit of measurement to estimate the additional cost and health outcome
(measured in QALYs, refer to Chapter 5.3.1) obtained through an intervention. The ICER
is computed by dividing the incremental cost (difference in average cost associated with
two interventions) by the incremental health benefits (difference in average QALY of two
interventions). Comparing different treatments in this manner answers questions about
whether an intervention is efficient and comparatively efficient. Mathematically, the
ICER is represented as follows:
(5.1)
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We let

and

signify the expected cost of the investigated treatment (

expected cost of the control treatment (
effectiveness of

and the

, respectively. Similarly, the expected health

and the expected health effectiveness of

are denoted by

and

, respectively.
In this dissertation, the parameters for the ICER are estimated from the simulation
model (presented in Chapter 4) and therefore the true population cost and effectiveness is
unknown with certainty. We can easily obtain confidence intervals (CIs) around the
sample costs and effects, however in cost-effectiveness analysis we care about the
uncertainty surrounding the ICER. This is not straightforward because when

and

are two normal random variables (each variable is associated with a mean and variance)
then the ratio has a standard Cauchy distribution. A Cauchy distributed variable does not
have a theoretical mean and variance however it is characterized by its mode and median
values. Therefore methods have been introduced to calculate CIs of Cauchy distributed
ICERs including nonparametric bootstrapping [Hunink et al, 1993; Briggs, 1997;
Campbell and Torgerson, 1999], Fieller‘s method [Chaudhary and Stearns, 1996], and the
delta method [O‘Brien et al., 1994]. We focus on the use of nonparametric bootstrapping
for significance testing of the ICER.
Black (1990) first introduced the incremental cost-effectiveness plane (Figure 5.1)
to explain the comparative cost-effectiveness of bootstrap ICER estimates. The horizontal
axis measures the incremental effectiveness of

and the incremental cost of

is

measured by the vertical axis. Each of the four quadrants implies a different level of costeffectiveness. Points that imply an intervention is more effective while saving money
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(dominant) fall in the south east (SE) quadrant. The north east (NE) quadrant indicates
cost-effectiveness where health effect is positive at higher cost. If points lay in the north
west (NW) quadrant, higher cost is associated with lower effectiveness and the
intervention is excluded. When both cost and effect are low, points sit in the south west
(SW) quadrant, and it is questionable whether a treatment is cost-effective compared to
the control treatment.
Δ Cost [(C), $US]
NW

NE

Excluded
(ΔE<0, ΔC>0)

Cost-Effective
(ΔE>0, ΔC>0)
Δ Effect [(E), QALY]

Questionable
(ΔE<0, ΔC<0)

Dominant
(ΔE>0, ΔC<0)

SW

SE

Figure 5.1: Incremental cost-effectiveness plane (NE = northeast quadrant; NW = northwest quadrant; SE =
southeast quadrant; SW = southwest quadrant; QALY = quality adjusted life year).

The cost-effectiveness plane helps answer questions about sampling uncertainty
(e.g. what is the probability

is cost-effective relative to

). Estimates of treatment

cost-effectiveness are important to health decision-makers who make determinations such
as whether or not a treatment should be reimbursed. General rules for deciding which
treatment (

or

) to choose are given in Table 5.1 [Cohen and Reynolds, 2008].
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Quadrant
NE (+)
SE (-)
SW (-)
NW (+)

Table 5.1: Implications of the cost-effectiveness plane.
Implication
(investigated treatment) is cost-effective – cost-increasing tradeoff
(investigated treatment) is dominant – choose
(investigated treatment) is questionable – cost-reducing tradeoff
(control treatment) is dominant – choose

We acknowledge that there are limitations with using the ICER statistic. When
significant uncertainty exists about the sign of the ICER it is difficult to interpret CIs
around the ICER. ICERs located in the NE and SW quadrants (both yielding positive
values) are hard to distinguish, as are ICERs falling in the NW and SE quadrants (both
having negative values). Different quadrants indicate very different conclusions about the
cost-effectiveness of the investigated treatment ( ). For example, ICERs located in the
SE quadrant indicate that

is dominated by

indicate opposite results, that

and ICERS sitting in the NW quadrant

is dominant. Therefore, reasonable caution should be

taken when interpreting cost-effectiveness studies.
5.2

Base-case analyses
This section presents the base case results of the simulation model to estimate

health and economic outcomes of alternative smoking cessation strategies. Results of a
cost-effectiveness analysis on base-case estimates are provided.
5.2.1 Simulation parameters
A cohort of 10,000 individuals was followed annually over a horizon of 1 year, 10
years, 30 years, and lifetime with output measures observed over five scenarios, one
simulation run for each intervention of interest and one simulation run with no treatment
attempt. Cost of treatment options and smoking-related disease and health utility values
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are summarized in Chapter 4.3. All costs and QALYs were discounted at an annual rate
of 3%.
To obtain tighter 95% confidence intervals around our performance values, 75
replications were carried out leading to sufficiently small half-widths for most output
variables. Common random numbers (CRNs) were applied to reduce stochastic variation
between runs. CRNs are particularly important in disease modeling when comparing
different treatment arms [Stout and Goldie, 2008].
5.2.2 Base-case results
The reader should refer to Table 5.2 for results of smoking prevalence over time.
Among smokers attempting to quit smoking, 2 year recidivism rates among those alive at
follow-up were the following: nicotine replacement treatment, 89.13%; bupropion,
81.14%; varenicline, 81.98%, and non-pharmacologic-assisted, 95.84%. Nicotine
replacement treatment, bupropion, varenicline, and non-pharmacologic-assisted had a
recidivism rate of 93.67%, 89.07%, 89.55%, 97.58% among those alive at 30 years,
respectively.
Table 5.2: Smoking prevalence among those alive at follow-up.
2 years
10 years
30 years
NRT
89.13
93.42
93.67
Bupropion
81.14
88.60
89.07
Varenicline
81.98
89.10
89.55
Non-pharmacologic-assisted
95.84
97.49
97.58
No Treatment
100.00
100.00
100.00
NRT = Nicotine Replacement Therapy; N/A = not applicable
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Lifetime
N/A
N/A
N/A
N/A
N/A

Table 5.3: Prevalence of smoking-related disease.
2 years
10 years
30 years
NRT
CHD
At least one stroke
One stroke
Multiple strokes
Lung Cancer
COPD
At least one co-morbidity
Bupropion
CHD
At least one stroke
One stroke
Multiple strokes
Lung Cancer
COPD
At least one co-morbidity
Varenicline
CHD
At least one stroke
One stroke
Multiple strokes
Lung Cancer
COPD
At least one co-morbidity
Non-pharmacologic-assisted
CHD
At least one stroke
One stroke
Multiple strokes
Lung Cancer
COPD
At least one co-morbidity
No Treatment
CHD
At least one stroke
One stroke
Multiple strokes
Lung Cancer
COPD
At least one co-morbidity

Lifetime

1.04
1.17
1.17
0.00
0.04
0.81
3.03

5.95
5.55
5.45
0.10
0.23
3.81
15.03

20.07
13.38
12.72
0.66
0.96
9.18
39.81

31.78
17.44
16.13
1.32
1.73
12.07
54.65

1.00
1.16
1.16
0.00
0.03
0.79
2.96

5.78
5.58
5.48
0.09
0.22
3.66
14.74

19.71
13.34
12.69
0.65
0.92
8.92
39.22

31.31
17.43
16.13
1.31
1.69
11.72
53.96

1.02
1.17
1.17
0.00
0.03
0.78
2.98

5.83
5.59
5.49
0.10
0.23
3.67
14.83

19.76
13.41
12.74
0.67
0.92
8.94
39.35

31.32
17.50
16.19
1.31
1.68
11.79
54.10

1.05
1.19
1.18
0.00
0.04
0.82
3.07

6.03
5.62
5.53
0.09
0.26
3.90
15.28

20.31
13.55
12.87
0.68
1.01
9.37
40.34

32.09
17.64
16.30
1.34
1.83
12.31
55.25

1.06
1.21
1.20
0.00
0.04
0.83
3.12

6.11
5.66
5.56
0.10
0.27
3.99
15.48

20.48
13.55
12.87
0.68
1.05
9.56
40.67

32.27
17.62
16.29
1.33
1.88
12.48
55.56

NRT = Nicotine Replacement Therapy; CHD = coronary heart disease; COPD = chronic obstructive
pulmonary disease
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Table 5.4: Prevalence of mortality.
2 years
10 years
NRT
CHD
Stroke
After one stroke
After multiple strokes
Lung Cancer
COPD
All-causes
Total
Bupropion
CHD
Stroke
After one stroke
After multiple strokes
Lung Cancer
COPD
All-causes
Total
Varenicline
CHD
Stroke
After one stroke
After multiple strokes
Lung Cancer
COPD
All-causes
Total
Non-pharmacologic-assisted
CHD
Stroke
After one stroke
After multiple strokes
Lung Cancer
COPD
All-causes
Total
No Treatment
CHD
Stroke
After one stroke
After multiple strokes
Lung Cancer
COPD
All-causes
Total

30 years

Lifetime

0.58
0.41
0.41
0.00
0.01
0.01
0.78
1.78

5.09
1.96
1.93
0.03
0.14
0.12
4.96
12.28

18.80
4.93
4.69
0.24
0.70
0.75
24.46
49.64

30.47
6.59
6.10
0.49
1.33
1.46
60.15
100.00

0.56
0.41
0.40
0.00
0.01
0.01
0.78
1.76

4.95
1.99
1.96
0.03
0.13
0.12
4.96
12.15

18.46
4.92
4.67
0.25
0.67
0.74
24.61
49.41

30.01
6.60
6.11
0.49
1.29
1.43
60.67
100.00

0.57
0.41
0.41
0.00
0.01
0.01
0.78
1.77

4.98
1.98
1.94
0.03
0.14
0.13
4.92
12.13

18.51
4.93
4.69
0.25
0.68
0.74
24.62
49.48

30.05
6.61
6.12
0.49
1.29
1.43
60.62
100.00

0.60
0.42
0.42
0.00
0.01
0.01
0.78
1.81

5.14
2.01
1.98
0.04
0.16
0.13
4.91
12.35

19.03
4.98
4.73
0.25
0.74
0.77
24.28
49.80

30.81
6.66
6.15
0.50
1.38
1.50
59.65
100.00

0.59
0.41
0.41
0.00
0.01
0.01
0.78
1.80

5.22
2.01
1.98
0.04
0.16
0.13
4.94
12.46

19.18
5.00
4.76
0.24
0.77
0.78
24.36
50.09

30.95
6.68
6.19
0.50
1.44
1.51
59.41
100.00

NRT = Nicotine Replacement Therapy; CHD = coronary heart disease; COPD = chronic obstructive
pulmonary disease
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Results of the base-case analysis found that on average bupropion was most
effective at reducing prevalence of lung cancer, COPD, stroke, and CHD. Without
intervention on average 55.56% of smokers will develop at least one smoking-related
condition over the lifetime of the simulation. Bupropion was also found on average to
reduce mortality prevalence the most. Compared with the non-pharmacologic-assisted
cessation option, all pharmacologic treatments (varenicline, NRT, and bupropion) prevent
smoking-related disease and death.
Base-case estimates of average cost and effect are summarized in Figure 5.2. The
average discounted QALYs a cohort of 10,000 former smokers could accumulate over a
lifetime is 15.14 (95% CI half-width of 0.01). Average QALYs attained over a lifetime
when smokers make no attempt at quitting is 14.48 (95% CI, 14.47-14.49) at an average
cost of $28626 (95% CI, $28464-$28788). The high cost associated with the no treatment
option is attributable to costs incurred from smoking-related disease.
No statistically significant differences were found in the average lifetime costs or
effects (QALYs) of bupropion (average cost between $28004-$28391, average effect
between 14.70-14.72) and varenicline (average cost between $28240-$28573, average
effect between 14.69-14.71). Bupropion was more effective and less costly than NRT. No
statistical differences were found in cost of bupropion and non-pharmacologic-assisted
cessation, however effectiveness increases with bupropion by 0.16 QALYs. Average cost
of varenicline was not statistically different from the other four treatment arms, however
it was statistically more effective than NRT, non-pharmacologic-assisted, and no
treatment. The population could increase their average effect over a lifetime by 0.14
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QALYs with NRT and 0.07 QALYs with non-pharmacologic-assisted cessation with no
statistical difference in average cost. All options to assist smoking cessation improved
health outcomes compared with no treatment, however only bupropion did so at lower
average cost.

Figure 5.2: Average discounted cost and effect of the five treatment arms (with 95% CIs).

Cost-effectiveness analyses were performed after 2 years, 10 years, 30 years, and
lifetime and were measured using the ICER statistic (refer to Section 5.1). We first
calculate ICERs by comparing each treatment option (NRT, bupropion, and varenicline,
non-pharmacologic-assisted) to no intervention. ICERs The results of the analysis are
presented in Table 5.5.
Regarding NRT, bupropion, and varenicline in reference to no treatment we
observe that cost-effectiveness improves over time. Costs in year 2, primarily attributable
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to treatment expense, are high and the health benefits are small. However, over a lifetime
smoking-related disease and mortality are less, and in turn costs are reduced because cost
of prevented disease is not accumulated and QALYs are higher. The ICER for bupropion
versus no treatment is the smallest (-$1857.71) followed by varenicline (-$1005.64).
Although the incremental cost of NRT is very low compared to bupropion and
varenicline, it is also less effective by 0.09 and 0.10 QALYs, respectively.
We have to take caution in assessing the non-pharmacologic-assisted option
compared to no treatment. This is a case where the negative ICER value is misleading.
Consider year 10 for example in which the incremental cost is negative (-$102.11),
however the incremental health effect is zero. Money is saved because incidences of
smoking-related conditions are reduced however, QALYs are not substantially impacted.
Table 5.5: Smoking cessation strategies compared to no treatment.
Treatment
2 years
10 years
30 years
lifetime
NRT
Incremental cost
$459.98
$316.34
$40.15
-$16.82
Incremental effect
0.01
0.04
0.10
0.13
ICER
$76,663.33 $7,869.15 $389.05
-$124.68
Bupropion
Incremental cost
$316.56
$114.36
-$317.76
-$428.76
Incremental effect
0.01
0.07
0.18
0.23
ICER
$30,733.98 $1,636.05 -$1,773.21 -$1,857.71
Varenicline
Incremental cost
$399.77
$247.51
-$105.78
-$219.33
Incremental effect
0.01
0.07
0.17
0.22
ICER
$40,792.86 $3,688.67 -$621.50
-$1,005.64
Non-pharmacologic-assisted
Incremental cost
-$15.52
-$102.11
-$198.29
-$180.78
Incremental effect
0.00
0.02
0.05
0.07
ICER
N/A
-$6,462.66 -$4,157.02 -$2,760.00

We next analyzed ICERs over a lifetime horizon by comparing the four smoking
cessation strategies to each other (NRT, bupropion, varenicline, non-pharmacologicassisted) in a successive stepwise manner based on costs incurred and effects (measured
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in QALYs) achieved. The four competing smoking cessation interventions were ranked
in order of increasing effectiveness and we compared cost-effectiveness of each strategy
to the strategy with the next highest QALY [Hallinen et al., 2010]. We want to determine
how available interventions compare to one another by obtaining maximum effect before
taking account of cost. Tables 5.6-5.8 show the results of the incremental analysis.
In Table 5.6 the negative ICER for varenicline means that by adopting varenicline
instead of NRT effect is increased and cost is reduced. NRT is dominated by varenicline
because it is more expensive and less effective and is therefore excluded. The ICERs are
recalculated (Table 5.7) for the three remaining treatment options. We observe from
Table 5.7 that non-pharmacologic-assisted is dominated by varenicline and is the next
alternative excluded. Table 5.8 compares bupropion versus varenicline to show that
bupropion is the dominant option.
Table 5.6: Stepwise comparison of smoking cessation interventions – step one.
Mean Cost
Mean
Incremental
Incremental ICER
Treatment
(C)
Effect* (E)
Cost (ΔC)
Effect (ΔE) (ΔC/ΔE)
Non-pharmacologic-assisted
$28,445.29 14.55
$28,445.29
14.55
$1955.37
NRT
$28,609.25 14.62
$163.95
0.07
$2359.63
Varenicline
$28,406.74 14.70
-$202.50
0.08
-$2436.19
Bupropion
$28,197.31 14.71
-$209.44
0.01
-$16452.10
* Effect is measured in QALYs
Table 5.7: Stepwise comparison of smoking cessation interventions – step two.
Mean Cost
Mean
Incremental Incremental
Treatment
(C)
Effect* (E)
Cost (ΔC)
Effect (ΔE)
Non-pharmacologic-assisted $28,445.29
14.55
$28,445.29 14.55
Varenicline
$28,406.74
14.70
-$38.55
0.15
Bupropion
$28,197.31
14.71
-$209.44
0.01
* Effect is measured in QALYs

ICER
(ΔC/ΔE)
$1955.37
-$252.62
-$16452.10

Table 5.8: Stepwise comparison of smoking cessation interventions – step three.
Mean Cost
Mean
Incremental Incremental
ICER
Treatment
(C)
Effect* (E)
Cost (ΔC)
Effect (ΔE)
(ΔC/ΔE)
Varenicline
$28,406.74
14.70
$28,406.74 14.70
$1932.45
Bupropion
$28,197.31
14.71
-$209.44
0.01
-$16452.10
* Effect is measured in QALYs
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5.3

Uncertainty Analyses
To allow for uncertainty in the economic evaluation, we first perform a

probabilistic sensitivity analysis on certain base-case estimates. Next, key parameters are
varied in univariate and multivariate sensitivity analyses to estimate the influence of
different parameters on the results. Various factors influence the choices of health policy
decision-makers, therefore we assess the sensitivity, acceptability, and efficiency of the
results obtained from the simulation.
5.3.1 Stochastic uncertainty in comparing costs and effects
Probabilistic sensitivity analysis was performed to confirm the validity of the
base-case incremental cost-effectiveness ratios (ICERs) for bupropion compared to
varenicline. In Section 5.2.2 we explained the uncertainty for the average cost and effect
and observed no statistical difference between bupropion and varenicline. Comparison of
bupropion to varenicline (Table 5.8) showed varenicline is dominated by bupropion. In
this section we assess the uncertainty for the incremental cost and effect ratio of
bupropion in reference to varenicline.
We applied the nonparametric bootstrap method using the cost and effect
estimates of the two treatment strategies obtained from the simulation to estimate a
confidence interval (95%) for the ICER. Four steps were required to produce a bootstrap
distribution for the ICER. First, paired cost and effect estimates from the simulation for
bupropion were sampled with replacement. The sample size was that of the original
sample [the number of replications in the DES model (i.e. 75)]. We obtain a new estimate
for average cost and effect with bupropion. Second, cost and effect pairs for the control
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treatment (i.e. varenicline) were sampled with replacement 75 times and a new estimate
for average cost and effect with the control treatment was attained. Next, the ICER of the
bootstrapped re-samples was computed. Sampling and calculation of the ICER was
performed 1000 times [Briggs et al., 1997; Campbell and Torgerson, 1999]. Construction
of the 95% confidence interval (CI) for the bootstrapped ICERs was achieved using the
percentile method [Briggs et al., 1997; Campbell and Torgerson, 1999]. ICER estimates
were ranked from smallest to largest and the lower and upper bounds of the CI were
represented by the 25th and 976th observations, respectively. The results of bootstrapping
to compare bupropion to varenicline are provided in Table 5.9.
Table 5.9: Incremental costs and effects (QALY) of 1,000 bootstrapped comparisons of Bupropion vs NRT.
Median ICER
Bupropion versus varenicline
Mean (CI)
[(ΔC/ ΔE), bootstrap CI]
Incremental Cost (ΔC)
-208.86
-13738.83
(-208723.42, 14518.98)
Incremental Effect (ΔE)
0.01

The 1000 ICER estimates were plotted on the cost-effectiveness plane (Figure
5.3) allowing us to evaluate uncertainty of our bootstrapped ICERs. In the base-case
analysis bupropion was found to dominate varenicline (indicated by the square in Figure
5.3). Although the estimates cover all four quadrants, indicating some uncertainty about
whether bupropion is dominant or cost-effective, the scatter plot shows bupropion to be
the dominant (more effective and less costly) treatment strategy with a high probability of
0.849. This supports the results of our base-case analysis. All four quadrant probabilities
are summarized in Table 5.10.
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Figure 5.3: Scatter plot of the 1,000 bootstrap pairs presented on the cost-effectiveness plane of bupropion
vs. varenicline.
Table 5.10: Quadrant probabilities of bupropion vs. varenicline.
Quadrant
Probability
NE (bupropion is cost-effective)
0.055
NW (varenicline dominates)
0.006
SW (bupropion is questionable)
0.090
SE (bupropion dominates)
0.849

5.3.2

Sensitivity analysis
Multiple one-way sensitivity analyses were performed on the lifetime ICER to

assess the robustness of the simulation when key input parameters are varied. These
parameters include all health state utility values of the smoking-related diseases, discount
rate on costs and QALYs, abstinence rates, and treatment costs. Holding other variables
constant, we varied the group of recidivism rates at a low and high value (refer to table
4.8) in a multi-way sensitivity analysis. Finally, sensitivity analysis is restricted to subsets
of the base-case population (e.g. assessing a group of all females).
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First, health state utilities were altered one at a time at the low value and high
value presented in Table 4.9. The discount rate (on both costs and QALYs) was adjusted
to 1% and 5% [Weinstein et al., 1996]. Results show that our model is strong in that none
of the incremental costs and incremental effects resulting from multiple univariate
sensitivity analyses on health state utilities differed from our base-case estimate. Basecase ICER for bupropion versus varenicline ( -$16452.10 per QALY saved) was sensitive
to the discount rate at 1% and 5% with a percent change to the base-case ICER of 29%
and -30%, respectively.
Next, we evaluated the efficacy rates (percent who stop smoking after the first
year) for bupropion and varenicline over the range obtained from our meta-analysis
(Table 4.2; Bupropion: 15%-30%, Varenicline: 18%-25%) using a step size of 1%.
Figure 5.5 shows the impact of the abstinence rate on cost per QALY for two treatments,
bupropion and varenicline. Then, we examined implications of treatment cost of
bupropion and varenicline when the price of treatment is $0 to $800 with step size $100.
Figure 5.6 shows the impact of varying the cost of bupropion and varenilcline. We
observe in Figure 5.5 that if the treatment efficacy of bupropion and varenicline are
equal, the cost per effect ($/QALY) is less for bupropion. Figure 5.6 shows that if cost
treatment for bupopion and varenicline are the same, cost per effect ($/QALY) is always
less for bupropion. Treatment efficacy is higher for bupropion in reference to varenicline,
therefore the QALY value (denominator) is always higher for bupriopion and the cost per
effect ratio is smaller. Therefore, bupropion is not only less expensive, but also more
effective.
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Figure 5.4: One-way sensitivity analysis of treatment efficacy of bupropion and varenicline.

T reatm en t

1950

B upropio n
V areniclin e
B ase-case - B upropion

C os t pe r e ffe c t ($ /Q A LY)

1940

B ase-case - V arenicline

1930

1920

1910

1900

1890
0

100

200

300

400

500

600

700

800

Tr e atme nt c os t ($ )

Figure 5.5: One-way sensitivity of treatment cost of bupropion and varenicline.
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Multi-way sensitivity analysis of recidivism rates was performed at low and high
values (Table 4.8). Refer to Table 5.11 for a summary of these results. Results of the
multi-way sensitivity analysis at low recidivism rates place the ICER in the NE (costeffective) quadrant. When recidivism is high, we find that the incremental cost of
bupropion compared to varenicline is -$317.86 compared to -$209.44 in the base-case.
Incremental effect is much smaller (0.0007 QALYs) than the base-case estimate (0.01
QALYs).
Table 5.11: Multi-way sensitivity analysis of recidivism rates.
Recidivism rate Incremental Cost (ΔC) Incremental Effect (ΔE) ICER (ΔC/ΔE)
Low value
$31.45
0.0228
$1,379.43
High value
-$317.86
0.0007
-$454,083.14

ICERs of bupropion in reference to varenicline of an all female and all male
population are evaluated. Very different results are estimated for an all female cohort
versus an all male cohort (Table 5.12). For an all female population, bupropion is less
costly (-$68.33) and slightly more effective (0.0203 QALYs) with an ICER of -$3371.
When the same simulation is run for an all male population, money is saved (-$92.77),
however health benefits are also lost (-0.0026). The ICER for an all male cohort is
$35,914 and a cost-reducing tradeoff must be made in choosing bupropion.
Last, costs and effects of a young cohort of all 18-year olds and individuals all 50
years of age at baseline (older age group) are estimated. Among both age groups cost is
saved while health benefits are gained (Table 5.12). Bupropion is dominant in
comparison to varenicline in both cases with ICERs of -$49,158 and -14,852 for
individuals 18 years of age and 50 years of age, respectively.
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Table 5.12: Sensitivity analysis by subset of the base-case population.
Parameter
Incremental Cost (ΔC) Incremental Effect (ΔE) ICER (ΔC/ΔE)
Sex
Female
-$68.33
0.0203
-$3,371.00
Male
-$92.77
-0.0026
$35,914.44
Age
18 years of age -$169.20
0.0034
-$49,158.22
50 years of age -$207.01
0.0139
-$14,852.23

5.4

Discussion
In this study, we used estimates of cost and QALY from the simulation presented

in Chapter 4 of smokers attempting pharmacologic smoking cessation treatment (NRT,
bupropion, and varenicline), non-pharmacologic-assisted cessation, and no treatment.
Cost effectiveness was estimated using the incremental cost-effectiveness ratio (ICER)
statistic. We first assessed the cost-effectiveness of the alternative treatment strategies by
comparing all treatment options to no treatment. Next a stepwise comparison of the
treatments was performed where decisions must be made between choosing bupropion
and varenicline. We found burpropion to be the dominant treatment for smoking
cessation.
Probabilistic sensitivity analysis confirmed the base-case findings for bupropion
versus varenicline and nonparametric bootstrapping showed that bupropion was dominant
with probability 84.9%. Our simulation was robust to changes in health state utility
values in our one-way sensitivity analysis. For all female versus all male populations
cost-effectiveness results differed greatly. In fact, the only case where bupropion was
cost-reducing resulted when the simulation was run for an all male population. This
implies that limited health care dollars are better off helping females versus males.
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Our results differ from previous cost-effectiveness studies of smoking cessation
therapies where varenicline was found to dominant in comparison to bupropion [Howard
et al., 2008]. One major difference between these studies and our research is that there
efficacy rates rely on a single clinical efficacy study. We obtain measures through a
meta-analysis of studies that investigate the efficacy of smoking cessation strategies. The
midpoint of the range is used as our base-case estimate of treatment efficacy. We perform
sensitivity analysis over the range of efficacy rates for bupropion and varenicline. In
future research, we will examine how the results change when the sample-size-weightedaverage for each treatment efficacy rate is applied.
In conclusion, we have shown that using discrete-event simulation is a powerful
tool with which we can examine comparative effectiveness of smoking cessation
strategies in a diverse patient population. We have further demonstrated that the longterm benefits of smoking cessation at a younger age significantly accrue over a patient‘s
lifetime. As such, it is critical for policymakers and insurers to encourage and consider
providing incentives for smoking cessation as early as possible and for clinicians and
patients to engage in shared decision making about which treatment strategy would be
best for the patient in terms of long-term abstinence, overall resources invested, and
cumulative health risks avoided over time.
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CHAPTER SIX
CONTRIBUTIONS

Chapter 2 introduced a discrete-event simulation (DES) model to quantify the
public health impact of the maternal obese and diabetic intrauterine environment on
obesity and diabetes prevalence in subsequent generations. The model was verified using
longitudinal data and we provided examples of the types of predictions our model can
generate. This dissertation is the first to apply discrete-event simulation to estimate the
impact of maternal obesity and diabetes on obesity and diabetes prevalence.
In Chapter 3 we used a mixed-methods approach, incorporating both statistical
methods and discrete-event simulation, to examine trends in weight-gain over time
among white and black women of child-bearing age in the US from 1980 to 2008 using
United States Census projections and National Health and Nutrition Examination Survey
(NHANES) data. We addressed the question of how to update changes in clinical
characteristics over time using data obtained through a cross-sectional study design. We
responded by developing a method to gain insights into the processes of change of
attributes using bootstrapping principles and mixed-effects regression models. This was
used to determine the change in BMI due to age in the simulation model allowing us to
examine trends in average BMI over generations at the population-level. Our results are
different than what is currently available in the literature in that our simulation
projections are based on the population prior to the onset of the obesity epidemic.
In Chapter 4 we constructed the first DES model to estimate the cost-effectiveness
of different smoking cessation strategies available to smokers in the US population.
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While previous models for comparing therapeutic smoking cessation options use efficacy
of treatment derived from a single study, we contribute to the literature by combining
results of different studies to model treatment efficacy. We described the data and model
assumptions and verification.
Chapter 5 provided results of the base-case model to evaluate smoking cessation
treatments. A sensitivity analysis was performed to understand the comparative
effectiveness and intrinsic value of four alternative smoking cessation strategies that can
improve clinical and patient decision-making and subsequent health and economic
outcomes at the population level. We provided examples of different analyses that can be
done using results of our model.
This dissertation contributes to the area of industrial engineering in healthcare by
providing two US population-level DES models to inform health policy decisions. US
population-level data structures require special handling and assumptions due to the
availability of medical data and the nature of the study design. The key element is to be
able to link mathematical models with the available data. Input measures are important
because the models are only as strong as the data and assumptions upon which they are
built. Data taken from multiple sources (United States Census, National Health and
Nutrition Examination Survey (NHANES), Centers for Disease Control and Prevention
(CDC)/National Center for Health Statistics (NCHS), and the literature) is not obtainable
in the desired format, and there is not one method for managing the data. Preparing a
valid representation of the data is crucial. We illustrate various methods for extracting
information from the data to make population-level predictions. Specifically,
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In Chapter 2, data from a longitudinal study was utilized to update attributes (i.e. BMI
level, diabetes status) of individuals in the simulation. Extracting necessary information
from this data involved different types of methods.


Using the mean and variance of the difference in average BMI (kg/m2) at baseline
and follow-up of the longitudinal study, annual changes to BMI were computed.
Updates to BMI values per year were approximated by a normal distribution.



Baseline estimates of diabetes prevalence taken from the longitudinal study and
information on increased likelihood of diabetes in obese versus not obese
individuals were used to derive baseline estimates of diabetes adjusted by obesity
status.



Annual probabilities of developing diabetes over time based on obesity status
were deduced using (a) baseline prevalence of obesity and (b) diabetes incidence
rates follow-up from the longitudinal study, and (c) the increased risk of diabetes
known to obese versus non-obese individuals. This was accomplished by applying
the cumulative geometric distribution.



Validating BMI and diabetes characteristics over a short time period (i.e. 8 years)
allowed us to make projections of diabetes prevalence accounting for obese
individuals having a different/higher risk of diabetes than non-obese individuals.



Furthermore, incorporating births into our model and keeping record of an
individual‘s mother‘s BMI and diabetes characteristics, allowed us to make
projections of diabetes prevalence over time when children of obese and/or
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diabetic women had an increased risk of diabetes from children not exposed to
obesity and/or diabetes during pregnancy.
In Chapter 3, cross-sectional data of the National Health and Nutrition Examination
Survey (NHANES) provided US population-level information on BMI.


We developed a method for extracting information from the cross-sectional data
set which allowed us to make US population-level estimates of change in
attributes (i.e. BMI) over time. This technique combined bootstrap statistical
methods and mixed-effects regression models. We described how we handled
cases of missing or insufficient data. This method allowed us to characterize the
change in weight-gain of white and black women of childbearing age in the US
prior to the onset of the obesity epidemic.



A method for validating our baseline (i.e. 1980) unadjusted average BMI
projections was presented.



Unadjusted projections of average BMI over a 28-year time period were made.
These projections of average BMI between 1980-2008 are fundamentally
different from what is currently available in the literature in that we make
projections of the population before the obesity epidemic took place. Previous
studies formulate projections on trends of diseases based on population data in
2000, at which time the obesity (and also diabetes) epidemics had already
initiated.



Estimates of baseline BMI and change in BMI over time from the statistical
analysis provided population-level estimates for the simulation model (presented

112

in Chapter 2). We proposed two methods for validating that individuals in the
simulation take on age appropriate characteristics (according to baseline crosssectional values): (1) validation of the Census age distribution, and (2) validation
of average BMI. We demonstrated these methods for projections of white women
of childbearing age.
In Chapter 4, information was extracted from data of multiple sources, presenting in
many different formats. Various statistical methods were applied to represent the data.


Disease incidence (for lung cancer, stroke, and CHD) required conversions from
rates of disease per annum to annual probabilities. For example, given the case rate
of stroke over a time period, we computed the probability of an individual having a
stroke in any given year. The cumulative exponential distribution function was
used in this computation.



In other cases (number of COPD exacerbations) where more than one occurrence
was possible in a year the binomial probability distribution was used to estimate
annual incidence.



Similarly, the number of exacerbations (out of the total annual COPD
exacerbation) that were major exacerbations was determined using the binomial
distribution formula.

In Chapter 5, we apply statistical methods to deduce information from the output
measures of the simulation (presented in Chapter 4).


We introduced the incremental cost-effective ratio (ICER) as a statistic for
quantifying cost-effectiveness of one treatment relative to another.
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Two different methods for comparing costs and health effects (QALYs) of the
alternative smoking cessation strategies using the ICER were provided. First, we
made separate comparisons of each treatment option (NRT, bupropion,
varenicline, and non-pharmacologic-assisted) to the no treatment control group to
quantify incremental cost per incremental health effect (QALY). Next, the four
treatment strategies were compared to each other in a successive stepwise manner
to gain information about how treatments perform in comparison to each other.



Like any statistical measure the ICER point estimate is associated with some
degree of uncertainty. Non-parametric bootstrap procedures allowed us to
estimate an uncertainty range for the ICER of two treatment options (bupropion
versus varenicline). We computed the 95% confidence interval for the
bootstrapped ICERs using the percentile method. Information about the
uncertainty of cost-effectiveness of a treatment option (bupropion) from the basecase estimations was provided.



Bootstrap estimates were analyzed using the cost-effectiveness plane method
which allowed us to address questions about the probability of cost-effectiveness
when comparing two treatment options (bupropion in reference to varenicline).
While the estimates resulting from the two models are topic-specific, many of the
modules created for these studies are generic and can easily be transferred to other
disease models. It is believed that these two models will aid decision makers in
recognizing the impact that preventative-care initiatives will have, and to evaluate
possible alternatives.

114

APPENDICES

115

Appendix A

Conditional Probability of Diabetes

Diabetes incidence rates taken from the SAHS study are provided in Table A.1.
Table A.1: Incident diabetes rates over the 7.5 year period.
Age cohort
Incidence
< 30
1.59
30 – 34
3.41
35 – 39
5.10
40 – 44
4.90

Prevalence of obesity in the SAHS population at baseline was 13.7 percent. Obese
individuals are assumed to be 10.723 times more likely to develop diabetes than
individuals who were not obese. The calculations are the following:
P(diabetes) = P(diabetes|obese)P(obese) + P(diabetes|not obese)P(not obese)
P(diabetes) = P(diabetes|obese)P(obese) + P(diabetes|not obese)(1-P(obese))
We know that: P(diabetes|obese) = (10.723)[P(diabetes|not obese)]
P(diabetes) = (10.723)(P(diabetes|not obese))P(obese)
+ P(diabetes|not obese)(1-P(obese))
For example, the derivation for the probability of diabetes for individuals less than 30
years of age given obesity status is provided.
0.0159 = (10.723)(P(diabetes|not obese))(0.137 ) + P(diabetes|not obese)(1-0.137)
Rearrange the terms:
0.0159 = P(diabetes|not obese)((10.723)(0.137) + (1-0.137))
P(diabetes|not obese) = 0.0068
P(diabetes|obese) = (10.723)(0.0068) = 0.0729
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This is the conditional probability of diabetes over 7.5 (round to 8) years. We want the
annual probability of developing diabetes given obesity status. We use the cumulative
distribution function (CDF) of a geometric random variable to determine the probability
of developing diabetes given obesity status in one year.
The CDF of a geometric random variable X is:
F(x) = P(X ≤ x) = 1 – (1-p)k

k = 1, 2, …

where p is the probability of succeeding on one try.
If we make independent attempts over and over, the geometric random variable counts
the number of attempts needed to obtain the first success. The CDF can be interpreted as
the probability of succeeding within k attempts.
Referring to the example, the probability of diabetes mellitus given obesity status for individuals
less than 30 years of age is the following:

P(diabetes|non-obese) = 1 – (1 – 0.0068)(1/7+1) = 0.0009
P(diabetes|obese) = 1 – (1 – 0.0731)(1/7+1) = 0.0094
Note that a potential drawback of using the geometric distribution is that it satisfies the
memoryless property.
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Appendix B
DES Distribution Input Parameters and Sensitivity Analysis Results
Table B.1: Distribution parameters for unadjusted BMI (kg/m2) projections and baseline BMI in the
simulation model.
White Women
Black Women
Age
Mean
SD
Mean
SD
15
21.5433
3.4282
22.4345
4.7431
16
21.7085
3.8278
22.7072
4.8048
17
21.9470
4.4140
22.9800
5.5909
18
22.1024
3.6399
23.2527
3.9708
19
22.2578
3.9704
23.5254
6.4735
20
22.4132
4.1106
23.7982
4.8807
21
22.5686
3.7814
24.0709
5.6945
22
22.7081
4.0617
24.3437
7.6422
23
22.8623
4.8443
24.6164
4.6313
24
23.0097
5.4161
24.8891
4.8132
25
23.1584
4.6566
25.1619
5.8713
26
23.3071
3.9366
25.4346
5.1306
27
23.4558
5.1977
25.7074
6.6887
28
23.6045
5.5674
26.4814
4.9856
29
23.7392
5.3541
26.6371
7.2702
30
23.8911
5.3520
26.7927
7.8335
31
24.0429
5.4873
26.9484
7.2204
32
24.1591
6.2145
27.1041
6.4911
33
24.2872
5.6085
27.2598
6.3269
34
24.4154
4.8513
27.4154
7.1926
35
24.5435
5.7674
27.5711
6.0806
36
24.6716
4.7902
27.7268
7.4565
37
24.7398
5.3306
27.8825
6.9395
38
24.7448
5.6666
28.0382
6.4886
39
24.8569
5.5871
28.1938
7.2594
40
24.9690
5.7611
28.3495
5.2604
41
25.0811
5.0280
28.5052
7.9332
42
25.1932
6.0894
28.6609
5.9704
43
25.3384
5.7728
28.8165
6.5386
44
25.4582
5.8072
28.9722
5.9604
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Table B.2: Distribution parameters for BMI (kg/m2) updates (annual change in BMI) in the simulation
model.
White Women
Black Women
Age
Mean
SD
Mean
SD
15
0.1652
0.6857
0.2727
0.7316
16
0.1652
0.6857
0.2727
0.7316
17
0.1554
0.4935
0.2727
0.7316
18
0.1554
0.4935
0.2727
0.7316
19
0.1554
0.4935
0.2727
0.7316
20
0.1554
0.4935
0.2727
0.7316
21
0.1554
0.4935
0.2727
0.7316
22
0.1542
0.3998
0.2727
0.7316
23
0.1542
0.3998
0.2727
0.7316
24
0.1487
0.4921
0.2727
0.7316
25
0.1487
0.4921
0.2727
0.7316
26
0.1487
0.4921
0.2727
0.7316
27
0.1487
0.4921
0.2727
0.7316
28
0.1487
0.4921
0.1557
0.6049
29
0.1518
0.6816
0.1557
0.6049
30
0.1518
0.6816
0.1557
0.6049
31
0.1518
0.6816
0.1557
0.6049
32
0.1281
0.5886
0.1557
0.6049
33
0.1281
0.5886
0.1557
0.6049
34
0.1281
0.5886
0.1557
0.6049
35
0.1281
0.5886
0.1557
0.6049
36
0.1281
0.5886
0.1557
0.6049
37
0.1253
0.5283
0.1557
0.6049
38
0.1121
0.7154
0.1557
0.6049
39
0.1121
0.7154
0.1557
0.6049
40
0.1121
0.7154
0.1557
0.6049
41
0.1121
0.7154
0.1557
0.6049
42
0.1121
0.7154
0.1557
0.6049
43
0.1198
1.0612
0.1557
0.6049
44
0.1198
1.0612
0.1557
0.6049
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Table B.3: Sensitivity analysis baseline BMI (kg/m2) for age 32 to 37 years.
Scenario 1
Scenario 2
Scenario 3
Age
Mean
SD
Mean
SD
Mean
SD
32
24.1591 0.3381
24.1235 0.3836
24.1947 0.5568
33
24.2872 0.3381
24.2279 0.3836
24.3466 0.5568
34
24.4154 0.3381
24.3323 0.3836
24.4984 0.5568
35
24.5435 0.3381
24.4368 0.3836
24.6502 0.5568
36
24.6716 0.3381
24.5412 0.3836
24.8021 0.5568
37
24.7398 0.2573
24.6327 0.2674
24.9539 0.5568
Scenario 4
Scenario 5
Age
Mean
SD
Mean
SD
32
24.1413 0.2556
24.1769 0.3257
33
24.2576 0.2556
24.3169 0.3257
34
24.3739 0.2556
24.4569 0.3257
35
24.4901 0.2556
24.5969 0.3257
36
24.6064 0.2556
24.7369 0.3257
37
24.6862 0.1856
24.8468 0.3067

Table B.4: Sensitivity analysis updates to BMI (kg/m2) for age 32 to 37 years.
Scenario 1
Scenario 2
Scenario 3
Age
Mean
SD
Mean
SD
Mean
SD
32
0.1281 0.5886
0.1044 0.9597
0.1518 0.6816
33
0.1281 0.5886
0.1044 0.9597
0.1518 0.6816
34
0.1281 0.5886
0.1044 0.9597
0.1518 0.6816
35
0.1281 0.5886
0.1044 0.9597
0.1518 0.6816
36
0.1281 0.5886
0.1044 0.9597
0.1518 0.6816
37
0.1253 0.5283
0.1121 0.7154
0.1518 0.6816
Scenario 4
Scenario 5
Age
Mean
SD
Mean
SD
32
0.1163 0.5629
0.1400 0.4503
33
0.1163 0.5629
0.1400 0.4503
34
0.1163 0.5629
0.1400 0.4503
35
0.1163 0.5629
0.1400 0.4503
36
0.1163 0.5629
0.1400 0.4503
37
0.1187 0.4447
0.1386 0.4312
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Table B.5: Sensitivity analysis results for average BMI (kg/m2) by age cohort and year.
Year
Age Cohort
Scenario 1 Scenario 2 Scenario 3 Scenario 4 Scenario 5
15 - 19
21.93
21.93
21.93
21.93
21.93
20 - 24
22.71
22.71
22.71
22.71
22.71
25 - 29
23.44
23.44
23.44
23.44
23.44
1980
30 - 34
24.15
24.11
24.18
24.13
24.16
35 - 39
24.70
24.63
24.80
24.67
24.75
40 - 44
25.21
25.21
25.21
25.21
25.21
15 - 44
23.50
23.48
23.52
23.49
23.51
15 - 19
22.42
22.42
22.42
22.42
22.42
20 - 24
23.20
23.20
23.20
23.20
23.20
25 - 29
23.47
23.47
23.47
23.47
23.47
1990
30 - 34
24.21
24.19
24.22
24.20
24.21
35 - 39
24.84
24.74
24.96
24.79
24.90
40 - 44
25.38
25.23
25.55
25.31
25.47
15 - 44
23.97
23.92
24.02
23.94
23.99
15 - 19
22.40
22.40
22.40
22.40
22.40
20 - 24
23.17
23.17
23.17
23.17
23.17
25 - 29
23.97
23.97
23.97
23.97
23.97
2000
30 - 34
24.69
24.68
24.71
24.69
24.70
35 - 39
24.83
24.71
24.94
24.77
24.89
40 - 44
25.43
25.30
25.58
25.37
25.51
15 - 44
24.20
24.15
24.25
24.18
24.23
15 - 19
22.41
22.41
22.41
22.41
22.41
20 - 24
23.16
23.16
23.16
23.16
23.16
25 - 29
23.93
23.93
23.93
23.93
23.93
2008
30 - 34
24.66
24.65
24.68
24.65
24.67
35 - 39
25.37
25.27
25.49
25.31
25.42
40 - 44
25.72
25.59
25.87
25.65
25.79
15 - 44
24.28
24.24
24.33
24.26
24.30
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Appendix C
Sample SAS Code
Libname nh1 "M\BMI by Birth Year";
data allw;
set nh1.nh0123;
where race='W';
newid=left(trim(id))||left(trim(seqn));
run;
/*numbers in dataset name correspond to birth years*/
/*age is centered to that the intercept is the lowest age
of the category*/
data w5559;
set allw;
where yob>='1955' and yob<'1959' and age>=15 and age<=23;
agec=age-15;
run;
*****************************************************
*regression example 5559 birth year -- 1955 and 1959*
*****************************************************
;
%let itnum=100;
%let sampsize=500;
*SRS means Simple Random Sampling;
proc surveyselect data=w5559 method=SRS n=&sampsize
reps=&itnum seed=40070 out=r5559;
run;
proc sort data=r5559; by replicate; run;
*** Full: With Random and method=REML *** ;
**NOTE: this includes the main effect of agecat ;
ods graphics on;
proc mixed data=r5559 method=REML noclprint=2 empirical;
class newid;
model bmi=agec/cl solution covb ddfm=res
outpm=output5559;
by replicate ;
random intercept/ subject=newid;
ods output SolutionF=betaparms;
run;
ods select fitstatistics;
proc reg data=output5559;
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model bmi=pred;
*
by replicate;
run;
quit;
ods graphics off;
proc contents data=betaparms; run;
*NOTE: First open the output data file betaparms_mix and
see if the effect columns correspond to what I have used
below;
* summary of parameter estimates*********;
data nh1.betaparms5559 (keep=replicate inter vinter tvinter
dfinter pvinter b1 vb1 tvb1 dfb1 pvb1);
retain inter tvinter dfinter b1 vb1 tvb1 dfb1 pvb1;
set betaparms;
by replicate;
if effect eq 'agec' then do;
b1 = estimate; vb1=StdErr; tvb1=tvalue; pvb1=Probt;
dfb1=df; end;
if effect eq 'Intercept' then do;
inter=estimate; vinter=StdErr; tvinter=tvalue;
pvinter=probt; dfinter=df; end;
if last.replicate then do;
output;
end;
else delete;
run;
proc means data=nh1.betaparms5559;
var b1 inter;
run;
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Appendix D
Computations for the Smoking Cessation DES Inputs
Table D.1: Age distribution of smokers.

Age

Number in
the US

18

2,282,042

Male
Number
of
Smokers
579,639

P(age|smoke)

2,162,940

Female
Number
of
Smokers
439,077

19

2,224,534

565,032

0.023

2,112,751

428,888

0.021

20

2,188,236

555,812

0.023

2,086,884

423,637

0.021

21

2,155,654

547,536

0.022

2,062,647

418,717

0.021

22

2,162,386

549,246

0.022

2,068,296

419,864

0.021

23

2,154,443

547,229

0.022

2,060,702

418,323

0.021

24

2,134,690

542,211

0.022

2,039,250

413,968

0.021

25

2,159,241

548,447

0.022

2,058,541

417,884

0.021

26

2,157,349

547,967

0.022

2,083,273

422,904

0.021

27

2,174,226

552,253

0.023

2,125,979

431,574

0.021

28

2,155,475

547,491

0.022

2,106,378

427,595

0.021

29

2,070,323

525,862

0.021

2,019,348

409,928

0.020

30

2,016,724

512,248

0.021

1,968,179

399,540

0.020

31

1,974,327

501,479

0.020

1,930,843

391,961

0.019

32

1,945,812

494,236

0.020

1,910,458

387,823

0.019

33

1,974,872

501,617

0.020

1,939,809

393,781

0.020

34

1,926,499

489,331

0.020

1,905,546

386,826

0.019

35

1,962,294

498,423

0.020

1,949,570

395,763

0.020

36

2,046,138

519,719

0.021

2,037,513

413,615

0.021

37

2,154,037

547,125

0.022

2,154,393

437,342

0.022

38

2,205,790

560,271

0.023

2,186,689

443,898

0.022

39

2,091,135

531,148

0.022

2,088,056

423,875

0.021

40

2,039,111

517,934

0.021

2,046,859

415,512

0.021

41

2,037,007

517,400

0.021

2,056,617

417,493

0.021

42

2,094,378

531,972

0.022

2,114,992

429,343

0.021

43

2,229,898

566,394

0.023

2,249,584

456,666

0.023

44

2,251,737

571,941

0.023

2,294,963

465,877

0.023

45

2,243,116

551,807

0.023

2,294,799

470,434

0.023

46

2,250,985

553,742

0.023

2,303,860

472,291

0.023

47

2,263,325

556,778

0.023

2,329,012

477,447

0.024

48

2,309,119

568,043

0.023

2,359,664

483,731

0.024

49

2,215,240

544,949

0.022

2,284,705

468,365

0.023

P(age|smoke)

Number in
the US

0.024
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0.022

50

2,206,404

542,775

0.022

2,280,669

467,537

0.023

51

2,151,695

529,317

0.022

2,237,945

458,779

0.023

52

2,088,599

513,795

0.021

2,180,369

446,976

0.022

53

2,085,043

512,921

0.021

2,169,687

444,786

0.022

54

1,979,014

486,837

0.020

2,082,836

426,981

0.021

55

1,912,892

470,571

0.019

2,024,202

414,961

0.021

56

1,847,781

454,554

0.019

1,959,188

401,634

0.020

57

1,774,943

436,636

0.018

1,892,368

387,935

0.019

58

1,769,416

435,276

0.018

1,886,571

386,747

0.019

59

1,693,399

416,576

0.017

1,820,005

373,101

0.019

60

1,692,209

416,283

0.017

1,823,349

373,787

0.019

61

1,665,640

409,747

0.017

1,800,563

369,115

0.018

62

1,356,184

333,621

0.014

1,481,887

303,787

0.015

63

1,271,328

312,747

0.013

1,399,272

286,851

0.014

64

1,254,678

308,651

0.013

1,394,030

285,776

0.014

65

1,244,631

131,931

0.005

1,396,116

114,482

0.006

66

1,123,417

119,082

0.005

1,274,736

104,528

0.005

67

1,021,173

108,244

0.004

1,172,433

96,140

0.005

68

971,772

103,008

0.004

1,124,069

92,174

0.005

69

919,903

97,510

0.004

1,073,613

88,036

0.004

70

877,737

93,040

0.004

1,036,312

84,978

0.004
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Table D.2: Probability tables for COPD exacerbations
COPD Level
x
f(x,p,n)
Milda

Moderate

Severe

0

0.5558

1

0.3516

2

0.0834

3

0.0088

4

0.0003

0

0.4606

1

0.3940

2

0.1264

3

0.0180

4

0.0010

0

0.4251

1

0.4054

2

0.1450

3

0.0230

b

c

4
0.0014
a. Exacerbation frequency (per annum) = 0.79
b. Exacerbation frequency (per annum) = 1.22
c. Exacerbation frequency (per annum) = 1.47
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Table D.3: Probability tables for minor COPD exacerbation
Mild COPDa
Moderate COPDb
Severe COPDc
n

x

f(x,p,n)

4

n

x

f(x,p,n)

4

n

x

f(x,p,n)

4

0

0.0000

0

0.0000

0

0.0001

1

0.0008

1

0.0013

1

0.0036

2

0.0191

2

0.0254

2

0.0486

3

0.1993

3

0.2252

3

0.2916

4

0.7807

4

0.7481

4

0.6561

3

3

3

0

0.0002

0

0.0003

0

0.0010

1

0.0102

1

0.0137

1

0.0270

2

0.1590

2

0.1816

2

0.2430

3

0.8306

3

0.8044

3

0.7290

2

2

2

0

0.0036

0

0.0049

0

0.0100

1

0.1128

1

0.1302

1

0.1800

2

0.8836

2

0.8649

2

0.8100

0

0.1000

1

1
0

0.0600

1
0

0.0700

1 0.9400
1 0.9300
1 0.9000
a. P(minor exacerbation | COPD exacerbation event) = 0.94
b. P(minor exacerbation | COPD exacerbation event) = 0.93
c. P(minor exacerbation | COPD exacerbation event) = 0.90
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